CHOYP_4EBP1.1.1	Q13541	m.12045	sp	4EBP1_HUMAN	56.881	109	42	4	42	147	12	118	9.41E-34	117	4EBP1_HUMAN	reviewed	Eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) (eIF4E-binding protein 1) (Phosphorylated heat- and acid-stable protein regulated by insulin 1) (PHAS-I)	EIF4EBP1	Homo sapiens (Human)	118	cellular response to hypoxia [GO:0071456]; G1/S transition of mitotic cell cycle [GO:0000082]; insulin receptor signaling pathway [GO:0008286]; IRES-dependent translational initiation [GO:0002192]; lung development [GO:0030324]; negative regulation of protein complex assembly [GO:0031333]; negative regulation of translational initiation [GO:0045947]; positive regulation of mitotic cell cycle [GO:0045931]; response to ethanol [GO:0045471]; response to ischemia [GO:0002931]; TOR signaling [GO:0031929]	GO:0000082; GO:0002192; GO:0002931; GO:0005654; GO:0005737; GO:0005829; GO:0008190; GO:0008286; GO:0030324; GO:0030371; GO:0031333; GO:0031929; GO:0043234; GO:0045471; GO:0045931; GO:0045947; GO:0071456	0	0	0	PF05456;	16	m.12045	604063.2	644443.4286	2124	1652333.273	1527421.333	1735288.1	992177.5	1408983.167	5571512.8	3639799.182	3.012776552
CHOYP_AAEL_AAEL008069.2.2	P46531	m.60920	sp	NOTC1_HUMAN	32.8	625	331	23	1703	2308	306	860	6.31E-68	261	NOTC1_HUMAN	reviewed	Neurogenic locus notch homolog protein 1 (Notch 1) (hN1) (Translocation-associated notch protein TAN-1) [Cleaved into: Notch 1 extracellular truncation (NEXT); Notch 1 intracellular domain (NICD)]	NOTCH1 TAN1	Homo sapiens (Human)	2555	"aortic valve morphogenesis [GO:0003180]; apoptotic process involved in embryonic digit morphogenesis [GO:1902263]; arterial endothelial cell differentiation [GO:0060842]; astrocyte differentiation [GO:0048708]; atrioventricular node development [GO:0003162]; atrioventricular valve morphogenesis [GO:0003181]; auditory receptor cell fate commitment [GO:0009912]; axonogenesis [GO:0007409]; branching morphogenesis of an epithelial tube [GO:0048754]; cardiac atrium morphogenesis [GO:0003209]; cardiac chamber formation [GO:0003207]; cardiac epithelial to mesenchymal transition [GO:0060317]; cardiac left ventricle morphogenesis [GO:0003214]; cardiac muscle cell proliferation [GO:0060038]; cardiac muscle tissue morphogenesis [GO:0055008]; cardiac right atrium morphogenesis [GO:0003213]; cardiac right ventricle formation [GO:0003219]; cardiac septum morphogenesis [GO:0060411]; cardiac vascular smooth muscle cell development [GO:0060948]; cardiac ventricle morphogenesis [GO:0003208]; cell differentiation in spinal cord [GO:0021515]; cell fate specification [GO:0001708]; cell migration involved in endocardial cushion formation [GO:0003273]; cellular response to follicle-stimulating hormone stimulus [GO:0071372]; cellular response to vascular endothelial growth factor stimulus [GO:0035924]; cilium morphogenesis [GO:0060271]; collecting duct development [GO:0072044]; compartment pattern specification [GO:0007386]; coronary artery morphogenesis [GO:0060982]; coronary vein morphogenesis [GO:0003169]; determination of left/right symmetry [GO:0007368]; distal tubule development [GO:0072017]; embryonic hindlimb morphogenesis [GO:0035116]; endocardial cell differentiation [GO:0060956]; endocardial cushion morphogenesis [GO:0003203]; endocardium development [GO:0003157]; endocardium morphogenesis [GO:0003160]; endoderm development [GO:0007492]; epithelial to mesenchymal transition [GO:0001837]; epithelial to mesenchymal transition involved in endocardial cushion formation [GO:0003198]; forebrain development [GO:0030900]; foregut morphogenesis [GO:0007440]; glomerular mesangial cell development [GO:0072144]; growth involved in heart morphogenesis [GO:0003241]; hair follicle morphogenesis [GO:0031069]; heart development [GO:0007507]; heart looping [GO:0001947]; heart trabecula morphogenesis [GO:0061384]; humoral immune response [GO:0006959]; immune response [GO:0006955]; inflammatory response to antigenic stimulus [GO:0002437]; interleukin-4 secretion [GO:0072602]; in utero embryonic development [GO:0001701]; keratinocyte differentiation [GO:0030216]; left/right axis specification [GO:0070986]; liver development [GO:0001889]; lung development [GO:0030324]; mesenchymal cell development [GO:0014031]; mitral valve formation [GO:0003192]; negative regulation of anoikis [GO:2000811]; negative regulation of auditory receptor cell differentiation [GO:0045608]; negative regulation of BMP signaling pathway [GO:0030514]; negative regulation of calcium ion-dependent exocytosis [GO:0045955]; negative regulation of canonical Wnt signaling pathway [GO:0090090]; negative regulation of catalytic activity [GO:0043086]; negative regulation of cell migration involved in sprouting angiogenesis [GO:0090051]; negative regulation of cell proliferation [GO:0008285]; negative regulation of cell-substrate adhesion [GO:0010812]; negative regulation of endothelial cell chemotaxis [GO:2001027]; negative regulation of glial cell proliferation [GO:0060253]; negative regulation of myoblast differentiation [GO:0045662]; negative regulation of myotube differentiation [GO:0010832]; negative regulation of neurogenesis [GO:0050768]; negative regulation of oligodendrocyte differentiation [GO:0048715]; negative regulation of ossification [GO:0030279]; negative regulation of osteoblast differentiation [GO:0045668]; negative regulation of photoreceptor cell differentiation [GO:0046533]; negative regulation of pro-B cell differentiation [GO:2000974]; negative regulation of stem cell differentiation [GO:2000737]; negative regulation of transcription, DNA-templated [GO:0045892]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; neural tube development [GO:0021915]; neuronal stem cell population maintenance [GO:0097150]; Notch signaling involved in heart development [GO:0061314]; Notch signaling pathway [GO:0007219]; Notch signaling pathway involved in regulation of secondary heart field cardioblast proliferation [GO:0003270]; oligodendrocyte differentiation [GO:0048709]; organ regeneration [GO:0031100]; pericardium morphogenesis [GO:0003344]; positive regulation of apoptotic process [GO:0043065]; positive regulation of astrocyte differentiation [GO:0048711]; positive regulation of BMP signaling pathway [GO:0030513]; positive regulation of cardiac muscle cell proliferation [GO:0060045]; positive regulation of cell migration [GO:0030335]; positive regulation of cell proliferation [GO:0008284]; positive regulation of endothelial cell differentiation [GO:0045603]; positive regulation of epithelial cell proliferation [GO:0050679]; positive regulation of epithelial to mesenchymal transition [GO:0010718]; positive regulation of JAK-STAT cascade [GO:0046427]; positive regulation of keratinocyte differentiation [GO:0045618]; positive regulation of neuroblast proliferation [GO:0002052]; positive regulation of Notch signaling pathway [GO:0045747]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of transcription from RNA polymerase II promoter in response to hypoxia [GO:0061419]; positive regulation of transcription of Notch receptor target [GO:0007221]; positive regulation of viral genome replication [GO:0045070]; positive regulation of viral transcription [GO:0050434]; prostate gland epithelium morphogenesis [GO:0060740]; pulmonary valve morphogenesis [GO:0003184]; regulation of epithelial cell proliferation involved in prostate gland development [GO:0060768]; regulation of extracellular matrix assembly [GO:1901201]; regulation of somitogenesis [GO:0014807]; regulation of transcription, DNA-templated [GO:0006355]; regulation of transcription from RNA polymerase II promoter involved in myocardial precursor cell differentiation [GO:0003256]; response to corticosteroid [GO:0031960]; response to lipopolysaccharide [GO:0032496]; response to muramyl dipeptide [GO:0032495]; secretory columnal luminar epithelial cell differentiation involved in prostate glandular acinus development [GO:0060528]; skeletal muscle cell differentiation [GO:0035914]; somatic stem cell division [GO:0048103]; spermatogenesis [GO:0007283]; sprouting angiogenesis [GO:0002040]; tissue regeneration [GO:0042246]; transcription initiation from RNA polymerase II promoter [GO:0006367]; tube formation [GO:0035148]; vasculogenesis involved in coronary vascular morphogenesis [GO:0060979]; venous endothelial cell differentiation [GO:0060843]; ventricular septum morphogenesis [GO:0060412]; ventricular trabecula myocardium morphogenesis [GO:0003222]"	GO:0000122; GO:0000139; GO:0001047; GO:0001190; GO:0001669; GO:0001701; GO:0001708; GO:0001837; GO:0001889; GO:0001947; GO:0002040; GO:0002052; GO:0002193; GO:0002437; GO:0003157; GO:0003160; GO:0003162; GO:0003169; GO:0003180; GO:0003181; GO:0003184; GO:0003192; GO:0003198; GO:0003203; GO:0003207; GO:0003208; GO:0003209; GO:0003213; GO:0003214; GO:0003219; GO:0003222; GO:0003241; GO:0003256; GO:0003270; GO:0003273; GO:0003344; GO:0003700; GO:0004857; GO:0004872; GO:0005509; GO:0005576; GO:0005634; GO:0005654; GO:0005789; GO:0005829; GO:0005886; GO:0005912; GO:0006355; GO:0006367; GO:0006955; GO:0006959; GO:0007219; GO:0007221; GO:0007283; GO:0007368; GO:0007386; GO:0007409; GO:0007440; GO:0007492; GO:0007507; GO:0008284; GO:0008285; GO:0009912; GO:0009986; GO:0010718; GO:0010812; GO:0010832; GO:0014031; GO:0014807; GO:0016021; GO:0016324; GO:0019899; GO:0021515; GO:0021915; GO:0030216; GO:0030279; GO:0030324; GO:0030335; GO:0030513; GO:0030514; GO:0030900; GO:0031069; GO:0031100; GO:0031490; GO:0031960; GO:0032495; GO:0032496; GO:0035116; GO:0035148; GO:0035914; GO:0035924; GO:0042246; GO:0043065; GO:0043086; GO:0043235; GO:0043565; GO:0045070; GO:0045603; GO:0045608; GO:0045618; GO:0045662; GO:0045668; GO:0045747; GO:0045892; GO:0045893; GO:0045944; GO:0045955; GO:0046427; GO:0046533; GO:0048103; GO:0048708; GO:0048709; GO:0048711; GO:0048715; GO:0048754; GO:0050434; GO:0050679; GO:0050768; GO:0055008; GO:0060038; GO:0060045; GO:0060253; GO:0060271; GO:0060317; GO:0060411; GO:0060412; GO:0060528; GO:0060740; GO:0060768; GO:0060842; GO:0060843; GO:0060948; GO:0060956; GO:0060979; GO:0060982; GO:0061314; GO:0061384; GO:0061419; GO:0070986; GO:0071372; GO:0072017; GO:0072044; GO:0072144; GO:0072602; GO:0090051; GO:0090090; GO:0097150; GO:1901201; GO:1902263; GO:2000737; GO:2000811; GO:2000974; GO:2001027	0	0	0	PF12796;PF11936;PF00008;PF07645;PF12661;PF06816;PF07684;PF00066;	40	m.60920	888328.0909	662510.3	191520.75	309585.4167	1334742.7	955913.9444	874828.75	1764646.769	1927912.2	612186.0667	1.811648748
CHOYP_ACAA2.1.1	Q3T0R7	m.30666	sp	THIM_BOVIN	62.814	398	144	2	1	398	1	394	0	532	THIM_BOVIN	reviewed	"3-ketoacyl-CoA thiolase, mitochondrial (EC 2.3.1.16) (Acetyl-CoA acyltransferase) (Beta-ketothiolase) (Mitochondrial 3-oxoacyl-CoA thiolase)"	ACAA2	Bos taurus (Bovine)	397	cellular response to hypoxia [GO:0071456]; fatty acid metabolic process [GO:0006631]; negative regulation of mitochondrial membrane permeability involved in apoptotic process [GO:1902109]; negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway [GO:1901029]	GO:0003988; GO:0005739; GO:0005743; GO:0006631; GO:0044822; GO:0070062; GO:0071456; GO:1901029; GO:1902109	PATHWAY: Lipid metabolism; fatty acid metabolism.	0	0	PF02803;PF00108;	70	m.30666	17109197	1619612	1334906.667	440148.3	1750810.75	1381721.9	556494.8	5368101.083	5101150.333	754468.75	0.591423466
CHOYP_AFG32.1.1	O43915	m.59373	sp	VEGFD_HUMAN	26.633	199	124	6	19	204	46	235	1.09E-07	56.6	VEGFD_HUMAN	reviewed	Vascular endothelial growth factor D (VEGF-D) (c-Fos-induced growth factor) (FIGF)	FIGF VEGFD	Homo sapiens (Human)	354	angiogenesis [GO:0001525]; cell proliferation [GO:0008283]; dopaminergic neuron differentiation [GO:0071542]; induction of positive chemotaxis [GO:0050930]; platelet degranulation [GO:0002576]; positive regulation of cell division [GO:0051781]; positive regulation of cell proliferation [GO:0008284]; positive regulation of interleukin-6 production [GO:0032755]; positive regulation of mast cell chemotaxis [GO:0060754]; regulation of vascular endothelial growth factor receptor signaling pathway [GO:0030947]; response to hypoxia [GO:0001666]; response to interleukin-1 [GO:0070555]; vascular endothelial growth factor receptor signaling pathway [GO:0048010]	GO:0001525; GO:0001666; GO:0002576; GO:0005161; GO:0005172; GO:0005576; GO:0005615; GO:0008283; GO:0008284; GO:0016020; GO:0030947; GO:0031093; GO:0032755; GO:0042056; GO:0048010; GO:0050930; GO:0051781; GO:0060754; GO:0070555; GO:0071542	0	0	0	PF00341;	192	m.59372	810407.25	40979	76584.25	333339.5	260042.3333	318579.5	237155.5	309434	663561.5	182198.6667	1.124610736
CHOYP_AGAP_AGAP002739.5.5	P46531	m.60925	sp	NOTC1_HUMAN	33.657	618	333	21	485	1088	306	860	6.72E-69	263	NOTC1_HUMAN	reviewed	Neurogenic locus notch homolog protein 1 (Notch 1) (hN1) (Translocation-associated notch protein TAN-1) [Cleaved into: Notch 1 extracellular truncation (NEXT); Notch 1 intracellular domain (NICD)]	NOTCH1 TAN1	Homo sapiens (Human)	2555	"aortic valve morphogenesis [GO:0003180]; apoptotic process involved in embryonic digit morphogenesis [GO:1902263]; arterial endothelial cell differentiation [GO:0060842]; astrocyte differentiation [GO:0048708]; atrioventricular node development [GO:0003162]; atrioventricular valve morphogenesis [GO:0003181]; auditory receptor cell fate commitment [GO:0009912]; axonogenesis [GO:0007409]; branching morphogenesis of an epithelial tube [GO:0048754]; cardiac atrium morphogenesis [GO:0003209]; cardiac chamber formation [GO:0003207]; cardiac epithelial to mesenchymal transition [GO:0060317]; cardiac left ventricle morphogenesis [GO:0003214]; cardiac muscle cell proliferation [GO:0060038]; cardiac muscle tissue morphogenesis [GO:0055008]; cardiac right atrium morphogenesis [GO:0003213]; cardiac right ventricle formation [GO:0003219]; cardiac septum morphogenesis [GO:0060411]; cardiac vascular smooth muscle cell development [GO:0060948]; cardiac ventricle morphogenesis [GO:0003208]; cell differentiation in spinal cord [GO:0021515]; cell fate specification [GO:0001708]; cell migration involved in endocardial cushion formation [GO:0003273]; cellular response to follicle-stimulating hormone stimulus [GO:0071372]; cellular response to vascular endothelial growth factor stimulus [GO:0035924]; cilium morphogenesis [GO:0060271]; collecting duct development [GO:0072044]; compartment pattern specification [GO:0007386]; coronary artery morphogenesis [GO:0060982]; coronary vein morphogenesis [GO:0003169]; determination of left/right symmetry [GO:0007368]; distal tubule development [GO:0072017]; embryonic hindlimb morphogenesis [GO:0035116]; endocardial cell differentiation [GO:0060956]; endocardial cushion morphogenesis [GO:0003203]; endocardium development [GO:0003157]; endocardium morphogenesis [GO:0003160]; endoderm development [GO:0007492]; epithelial to mesenchymal transition [GO:0001837]; epithelial to mesenchymal transition involved in endocardial cushion formation [GO:0003198]; forebrain development [GO:0030900]; foregut morphogenesis [GO:0007440]; glomerular mesangial cell development [GO:0072144]; growth involved in heart morphogenesis [GO:0003241]; hair follicle morphogenesis [GO:0031069]; heart development [GO:0007507]; heart looping [GO:0001947]; heart trabecula morphogenesis [GO:0061384]; humoral immune response [GO:0006959]; immune response [GO:0006955]; inflammatory response to antigenic stimulus [GO:0002437]; interleukin-4 secretion [GO:0072602]; in utero embryonic development [GO:0001701]; keratinocyte differentiation [GO:0030216]; left/right axis specification [GO:0070986]; liver development [GO:0001889]; lung development [GO:0030324]; mesenchymal cell development [GO:0014031]; mitral valve formation [GO:0003192]; negative regulation of anoikis [GO:2000811]; negative regulation of auditory receptor cell differentiation [GO:0045608]; negative regulation of BMP signaling pathway [GO:0030514]; negative regulation of calcium ion-dependent exocytosis [GO:0045955]; negative regulation of canonical Wnt signaling pathway [GO:0090090]; negative regulation of catalytic activity [GO:0043086]; negative regulation of cell migration involved in sprouting angiogenesis [GO:0090051]; negative regulation of cell proliferation [GO:0008285]; negative regulation of cell-substrate adhesion [GO:0010812]; negative regulation of endothelial cell chemotaxis [GO:2001027]; negative regulation of glial cell proliferation [GO:0060253]; negative regulation of myoblast differentiation [GO:0045662]; negative regulation of myotube differentiation [GO:0010832]; negative regulation of neurogenesis [GO:0050768]; negative regulation of oligodendrocyte differentiation [GO:0048715]; negative regulation of ossification [GO:0030279]; negative regulation of osteoblast differentiation [GO:0045668]; negative regulation of photoreceptor cell differentiation [GO:0046533]; negative regulation of pro-B cell differentiation [GO:2000974]; negative regulation of stem cell differentiation [GO:2000737]; negative regulation of transcription, DNA-templated [GO:0045892]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; neural tube development [GO:0021915]; neuronal stem cell population maintenance [GO:0097150]; Notch signaling involved in heart development [GO:0061314]; Notch signaling pathway [GO:0007219]; Notch signaling pathway involved in regulation of secondary heart field cardioblast proliferation [GO:0003270]; oligodendrocyte differentiation [GO:0048709]; organ regeneration [GO:0031100]; pericardium morphogenesis [GO:0003344]; positive regulation of apoptotic process [GO:0043065]; positive regulation of astrocyte differentiation [GO:0048711]; positive regulation of BMP signaling pathway [GO:0030513]; positive regulation of cardiac muscle cell proliferation [GO:0060045]; positive regulation of cell migration [GO:0030335]; positive regulation of cell proliferation [GO:0008284]; positive regulation of endothelial cell differentiation [GO:0045603]; positive regulation of epithelial cell proliferation [GO:0050679]; positive regulation of epithelial to mesenchymal transition [GO:0010718]; positive regulation of JAK-STAT cascade [GO:0046427]; positive regulation of keratinocyte differentiation [GO:0045618]; positive regulation of neuroblast proliferation [GO:0002052]; positive regulation of Notch signaling pathway [GO:0045747]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of transcription from RNA polymerase II promoter in response to hypoxia [GO:0061419]; positive regulation of transcription of Notch receptor target [GO:0007221]; positive regulation of viral genome replication [GO:0045070]; positive regulation of viral transcription [GO:0050434]; prostate gland epithelium morphogenesis [GO:0060740]; pulmonary valve morphogenesis [GO:0003184]; regulation of epithelial cell proliferation involved in prostate gland development [GO:0060768]; regulation of extracellular matrix assembly [GO:1901201]; regulation of somitogenesis [GO:0014807]; regulation of transcription, DNA-templated [GO:0006355]; regulation of transcription from RNA polymerase II promoter involved in myocardial precursor cell differentiation [GO:0003256]; response to corticosteroid [GO:0031960]; response to lipopolysaccharide [GO:0032496]; response to muramyl dipeptide [GO:0032495]; secretory columnal luminar epithelial cell differentiation involved in prostate glandular acinus development [GO:0060528]; skeletal muscle cell differentiation [GO:0035914]; somatic stem cell division [GO:0048103]; spermatogenesis [GO:0007283]; sprouting angiogenesis [GO:0002040]; tissue regeneration [GO:0042246]; transcription initiation from RNA polymerase II promoter [GO:0006367]; tube formation [GO:0035148]; vasculogenesis involved in coronary vascular morphogenesis [GO:0060979]; venous endothelial cell differentiation [GO:0060843]; ventricular septum morphogenesis [GO:0060412]; ventricular trabecula myocardium morphogenesis [GO:0003222]"	GO:0000122; GO:0000139; GO:0001047; GO:0001190; GO:0001669; GO:0001701; GO:0001708; GO:0001837; GO:0001889; GO:0001947; GO:0002040; GO:0002052; GO:0002193; GO:0002437; GO:0003157; GO:0003160; GO:0003162; GO:0003169; GO:0003180; GO:0003181; GO:0003184; GO:0003192; GO:0003198; GO:0003203; GO:0003207; GO:0003208; GO:0003209; GO:0003213; GO:0003214; GO:0003219; GO:0003222; GO:0003241; GO:0003256; GO:0003270; GO:0003273; GO:0003344; GO:0003700; GO:0004857; GO:0004872; GO:0005509; GO:0005576; GO:0005634; GO:0005654; GO:0005789; GO:0005829; GO:0005886; GO:0005912; GO:0006355; GO:0006367; GO:0006955; GO:0006959; GO:0007219; GO:0007221; GO:0007283; GO:0007368; GO:0007386; GO:0007409; GO:0007440; GO:0007492; GO:0007507; GO:0008284; GO:0008285; GO:0009912; GO:0009986; GO:0010718; GO:0010812; GO:0010832; GO:0014031; GO:0014807; GO:0016021; GO:0016324; GO:0019899; GO:0021515; GO:0021915; GO:0030216; GO:0030279; GO:0030324; GO:0030335; GO:0030513; GO:0030514; GO:0030900; GO:0031069; GO:0031100; GO:0031490; GO:0031960; GO:0032495; GO:0032496; GO:0035116; GO:0035148; GO:0035914; GO:0035924; GO:0042246; GO:0043065; GO:0043086; GO:0043235; GO:0043565; GO:0045070; GO:0045603; GO:0045608; GO:0045618; GO:0045662; GO:0045668; GO:0045747; GO:0045892; GO:0045893; GO:0045944; GO:0045955; GO:0046427; GO:0046533; GO:0048103; GO:0048708; GO:0048709; GO:0048711; GO:0048715; GO:0048754; GO:0050434; GO:0050679; GO:0050768; GO:0055008; GO:0060038; GO:0060045; GO:0060253; GO:0060271; GO:0060317; GO:0060411; GO:0060412; GO:0060528; GO:0060740; GO:0060768; GO:0060842; GO:0060843; GO:0060948; GO:0060956; GO:0060979; GO:0060982; GO:0061314; GO:0061384; GO:0061419; GO:0070986; GO:0071372; GO:0072017; GO:0072044; GO:0072144; GO:0072602; GO:0090051; GO:0090090; GO:0097150; GO:1901201; GO:1902263; GO:2000737; GO:2000811; GO:2000974; GO:2001027	0	0	0	PF12796;PF11936;PF00008;PF07645;PF12661;PF06816;PF07684;PF00066;	201	m.60925	163769.5	294550.6667	81522.66667	35825	565140.75	424707.25	104017.6667	3123810.5	1687258.333	322218.8889	4.963157467
CHOYP_BIRC2.5.13	Q13490	m.24445	sp	BIRC2_HUMAN	35.961	203	121	4	7	201	167	368	7.78E-33	129	BIRC2_HUMAN	reviewed	Baculoviral IAP repeat-containing protein 2 (EC 6.3.2.-) (Cellular inhibitor of apoptosis 1) (C-IAP1) (IAP homolog B) (Inhibitor of apoptosis protein 2) (hIAP-2) (hIAP2) (RING finger protein 48) (TNFR2-TRAF-signaling complex protein 2)	BIRC2 API1 MIHB RNF48	Homo sapiens (Human)	618	"cell surface receptor signaling pathway [GO:0007166]; cellular component disassembly involved in execution phase of apoptosis [GO:0006921]; I-kappaB kinase/NF-kappaB signaling [GO:0007249]; inhibition of cysteine-type endopeptidase activity involved in apoptotic process [GO:1990001]; necroptotic process [GO:0070266]; negative regulation of apoptotic process [GO:0043066]; negative regulation of ripoptosome assembly involved in necroptotic process [GO:1902443]; NIK/NF-kappaB signaling [GO:0038061]; placenta development [GO:0001890]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; positive regulation of protein K48-linked ubiquitination [GO:1902524]; positive regulation of protein K63-linked ubiquitination [GO:1902523]; positive regulation of protein monoubiquitination [GO:1902527]; proteasome-mediated ubiquitin-dependent protein catabolic process [GO:0043161]; protein heterooligomerization [GO:0051291]; protein polyubiquitination [GO:0000209]; regulation of apoptotic process [GO:0042981]; regulation of cell cycle [GO:0051726]; regulation of cell differentiation [GO:0045595]; regulation of cell proliferation [GO:0042127]; regulation of cysteine-type endopeptidase activity [GO:2000116]; regulation of inflammatory response [GO:0050727]; regulation of innate immune response [GO:0045088]; regulation of necroptotic process [GO:0060544]; regulation of necrotic cell death [GO:0010939]; regulation of nucleotide-binding oligomerization domain containing signaling pathway [GO:0070424]; regulation of reactive oxygen species metabolic process [GO:2000377]; regulation of RIG-I signaling pathway [GO:0039535]; regulation of toll-like receptor signaling pathway [GO:0034121]; regulation of transcription, DNA-templated [GO:0006355]; regulation of tumor necrosis factor-mediated signaling pathway [GO:0010803]; response to cAMP [GO:0051591]; response to ethanol [GO:0045471]; response to hypoxia [GO:0001666]; transcription, DNA-templated [GO:0006351]; TRIF-dependent toll-like receptor signaling pathway [GO:0035666]; tumor necrosis factor-mediated signaling pathway [GO:0033209]"	GO:0000209; GO:0001666; GO:0001741; GO:0001890; GO:0003713; GO:0004842; GO:0005634; GO:0005737; GO:0005829; GO:0006351; GO:0006355; GO:0006921; GO:0007166; GO:0007249; GO:0008270; GO:0009898; GO:0010803; GO:0010939; GO:0016740; GO:0016874; GO:0033209; GO:0034121; GO:0035631; GO:0035666; GO:0038061; GO:0039535; GO:0042127; GO:0042981; GO:0043027; GO:0043066; GO:0043123; GO:0043161; GO:0045088; GO:0045121; GO:0045471; GO:0045595; GO:0047485; GO:0050727; GO:0051291; GO:0051591; GO:0051726; GO:0060544; GO:0070266; GO:0070424; GO:1902443; GO:1902523; GO:1902524; GO:1902527; GO:1990001; GO:2000116; GO:2000377	0	0	0	PF00653;PF00619;	353	m.24445	561566	215112	523219.5	4650303.667	1501028.5	194827	348110	973006.5	23519	2367720.5	0.524367544
CHOYP_BRAFLDRAFT_127065.2.7	Q15063	m.5835	sp	POSTN_HUMAN	31.786	280	170	5	47	325	108	367	1.97E-35	139	POSTN_HUMAN	reviewed	Periostin (PN) (Osteoblast-specific factor 2) (OSF-2)	POSTN OSF2	Homo sapiens (Human)	836	bone regeneration [GO:1990523]; cell adhesion [GO:0007155]; cellular response to fibroblast growth factor stimulus [GO:0044344]; cellular response to transforming growth factor beta stimulus [GO:0071560]; cellular response to tumor necrosis factor [GO:0071356]; cellular response to vitamin K [GO:0071307]; extracellular matrix organization [GO:0030198]; negative regulation of cell-matrix adhesion [GO:0001953]; negative regulation of substrate adhesion-dependent cell spreading [GO:1900025]; neuron projection extension [GO:1990138]; positive regulation of chemokine (C-C motif) ligand 2 secretion [GO:1904209]; positive regulation of smooth muscle cell migration [GO:0014911]; regulation of Notch signaling pathway [GO:0008593]; regulation of systemic arterial blood pressure [GO:0003073]; response to estradiol [GO:0032355]; response to hypoxia [GO:0001666]; response to mechanical stimulus [GO:0009612]; response to muscle activity [GO:0014850]; skeletal system development [GO:0001501]	GO:0001501; GO:0001666; GO:0001953; GO:0003073; GO:0005578; GO:0005615; GO:0005802; GO:0007155; GO:0008201; GO:0008593; GO:0009612; GO:0014850; GO:0014911; GO:0030198; GO:0031012; GO:0031594; GO:0032355; GO:0044344; GO:0046872; GO:0050839; GO:0071307; GO:0071356; GO:0071560; GO:1900025; GO:1904209; GO:1990138; GO:1990523	0	0	0	PF02469;	569	m.5835	694072.3333	2883392.5	5737334.5	17274617	6446281.667	4810767	3602839.5	4933434	10010335.5	21864219.5	1.368870593
CHOYP_BRAFLDRAFT_127065.6.7	Q62009	m.30727	sp	POSTN_MOUSE	34.221	263	163	7	46	302	110	368	8.17E-37	142	POSTN_MOUSE	reviewed	Periostin (PN) (Osteoblast-specific factor 2) (OSF-2)	Postn Osf2	Mus musculus (Mouse)	838	bone regeneration [GO:1990523]; cell adhesion [GO:0007155]; cellular response to fibroblast growth factor stimulus [GO:0044344]; cellular response to transforming growth factor beta stimulus [GO:0071560]; cellular response to tumor necrosis factor [GO:0071356]; cellular response to vitamin K [GO:0071307]; extracellular matrix organization [GO:0030198]; negative regulation of cell-matrix adhesion [GO:0001953]; negative regulation of substrate adhesion-dependent cell spreading [GO:1900025]; neuron projection extension [GO:1990138]; positive regulation of chemokine (C-C motif) ligand 2 secretion [GO:1904209]; positive regulation of smooth muscle cell migration [GO:0014911]; regulation of Notch signaling pathway [GO:0008593]; regulation of systemic arterial blood pressure [GO:0003073]; response to estradiol [GO:0032355]; response to hypoxia [GO:0001666]; response to mechanical stimulus [GO:0009612]; response to muscle activity [GO:0014850]; tissue development [GO:0009888]	GO:0001666; GO:0001953; GO:0003073; GO:0005578; GO:0005615; GO:0005802; GO:0007155; GO:0008201; GO:0008593; GO:0009612; GO:0009888; GO:0014850; GO:0014911; GO:0030198; GO:0031012; GO:0031594; GO:0032355; GO:0044344; GO:0046872; GO:0050839; GO:0071307; GO:0071356; GO:0071560; GO:1900025; GO:1904209; GO:1990138; GO:1990523	0	0	0	PF02469;	570	m.30727	1488127.364	788091.8	333455.8333	12082867.53	1952572.545	1915867	162451.6667	279104.5714	200931.5714	3481897.583	0.362884388
CHOYP_BRAFLDRAFT_68934.2.2	O09164	m.62964	sp	SODE_MOUSE	30.682	88	57	3	1	87	79	163	1.81E-06	48.9	SODE_MOUSE	reviewed	Extracellular superoxide dismutase [Cu-Zn] (EC-SOD) (EC 1.15.1.1)	Sod3	Mus musculus (Mouse)	251	response to copper ion [GO:0046688]; response to hypoxia [GO:0001666]; response to reactive oxygen species [GO:0000302]	GO:0000302; GO:0001666; GO:0004784; GO:0005507; GO:0005615; GO:0005634; GO:0005796; GO:0005802; GO:0008270; GO:0031012; GO:0046688; GO:0070062	0	0	cd00305;	PF00080;	880	m.62964	186559	208482	1126469.5	365970	206897.75	35060	79125	547840.3333	44132	51690	0.361848359
CHOYP_BRAFLDRAFT_99019.8.8	Q07352	m.62208	sp	TISB_HUMAN	78.125	96	20	1	65	159	88	183	1.57E-47	167	TISB_HUMAN	reviewed	"Zinc finger protein 36, C3H1 type-like 1 (Butyrate response factor 1) (EGF-response factor 1) (ERF-1) (Protein TIS11B)"	ZFP36L1 BERG36 BRF1 ERF1 RNF162B TIS11B	Homo sapiens (Human)	338	"3'-UTR-mediated mRNA destabilization [GO:0061158]; apoptotic process [GO:0006915]; cell proliferation [GO:0008283]; cellular response to cAMP [GO:0071320]; cellular response to epidermal growth factor stimulus [GO:0071364]; cellular response to fibroblast growth factor stimulus [GO:0044344]; cellular response to glucocorticoid stimulus [GO:0071385]; cellular response to hypoxia [GO:0071456]; cellular response to insulin stimulus [GO:0032869]; cellular response to peptide hormone stimulus [GO:0071375]; cellular response to phorbol 13-acetate 12-myristate [GO:1904628]; cellular response to raffinose [GO:0097403]; cellular response to salt stress [GO:0071472]; cellular response to transforming growth factor beta stimulus [GO:0071560]; cellular response to tumor necrosis factor [GO:0071356]; chorio-allantoic fusion [GO:0060710]; ERK1 and ERK2 cascade [GO:0070371]; heart development [GO:0007507]; MAPK cascade [GO:0000165]; mesendoderm development [GO:0048382]; mRNA transport [GO:0051028]; multicellular organism growth [GO:0035264]; negative regulation of erythrocyte differentiation [GO:0045647]; neural tube development [GO:0021915]; nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay [GO:0000288]; nuclear-transcribed mRNA catabolic process, deadenylation-independent decay [GO:0031086]; p38MAPK cascade [GO:0038066]; phosphatidylinositol 3-kinase signaling [GO:0014065]; positive regulation of fat cell differentiation [GO:0045600]; positive regulation of intracellular mRNA localization [GO:1904582]; positive regulation of monocyte differentiation [GO:0045657]; positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay [GO:1900153]; proepicardium development [GO:0003342]; protein kinase B signaling [GO:0043491]; regulation of gene expression [GO:0010468]; regulation of keratinocyte apoptotic process [GO:1902172]; regulation of keratinocyte differentiation [GO:0045616]; regulation of keratinocyte proliferation [GO:0010837]; regulation of mRNA 3'-end processing [GO:0031440]; regulation of mRNA stability [GO:0043488]; regulation of myoblast differentiation [GO:0045661]; regulation of stem cell proliferation [GO:0072091]; response to wounding [GO:0009611]; spongiotrophoblast layer development [GO:0060712]; T cell differentiation in thymus [GO:0033077]; vasculogenesis [GO:0001570]"	GO:0000165; GO:0000288; GO:0000932; GO:0001570; GO:0003342; GO:0003677; GO:0003700; GO:0003729; GO:0003730; GO:0005634; GO:0005737; GO:0005829; GO:0006915; GO:0007507; GO:0008283; GO:0009611; GO:0010468; GO:0010837; GO:0014065; GO:0021915; GO:0030529; GO:0031086; GO:0031440; GO:0032869; GO:0033077; GO:0035264; GO:0035925; GO:0038066; GO:0043488; GO:0043491; GO:0044344; GO:0044822; GO:0045600; GO:0045616; GO:0045647; GO:0045657; GO:0045661; GO:0046872; GO:0048382; GO:0051028; GO:0060710; GO:0060712; GO:0061158; GO:0070371; GO:0071320; GO:0071356; GO:0071364; GO:0071375; GO:0071385; GO:0071456; GO:0071472; GO:0071560; GO:0071889; GO:0072091; GO:0097403; GO:1900153; GO:1902172; GO:1904582; GO:1904628	0	0	0	PF04553;PF00642;	1069	m.62207	444133	28129368.4	19495068	2400805.333	6544654.906	78071.66667	364224	834174	1709445	66591.375	0.05353956
CHOYP_CAN5.1.1	P80404	m.42243	sp	GABT_HUMAN	51.02	490	231	2	20	500	9	498	0	534	GABT_HUMAN	reviewed	"4-aminobutyrate aminotransferase, mitochondrial (EC 2.6.1.19) ((S)-3-amino-2-methylpropionate transaminase) (EC 2.6.1.22) (GABA aminotransferase) (GABA-AT) (Gamma-amino-N-butyrate transaminase) (GABA transaminase) (GABA-T) (L-AIBAT)"	ABAT GABAT	Homo sapiens (Human)	500	aging [GO:0007568]; behavioral response to cocaine [GO:0048148]; cerebellum development [GO:0021549]; copulation [GO:0007620]; exploration behavior [GO:0035640]; gamma-aminobutyric acid biosynthetic process [GO:0009449]; gamma-aminobutyric acid catabolic process [GO:0009450]; locomotory behavior [GO:0007626]; negative regulation of blood pressure [GO:0045776]; negative regulation of dopamine secretion [GO:0033602]; negative regulation of gamma-aminobutyric acid secretion [GO:0014053]; negative regulation of platelet aggregation [GO:0090331]; neurotransmitter catabolic process [GO:0042135]; positive regulation of aspartate secretion [GO:1904450]; positive regulation of dopamine metabolic process [GO:0045964]; positive regulation of heat generation [GO:0031652]; positive regulation of inhibitory postsynaptic potential [GO:0097151]; positive regulation of insulin secretion [GO:0032024]; positive regulation of prolactin secretion [GO:1902722]; positive regulation of uterine smooth muscle contraction [GO:0070474]; response to drug [GO:0042493]; response to ethanol [GO:0045471]; response to hypoxia [GO:0001666]; response to iron ion [GO:0010039]; response to nicotine [GO:0035094]	GO:0001666; GO:0003867; GO:0005739; GO:0005759; GO:0007568; GO:0007620; GO:0007626; GO:0009449; GO:0009450; GO:0010039; GO:0014053; GO:0021549; GO:0030170; GO:0031652; GO:0032024; GO:0032144; GO:0032145; GO:0033602; GO:0035094; GO:0035640; GO:0042135; GO:0042493; GO:0042803; GO:0043005; GO:0045471; GO:0045776; GO:0045964; GO:0046872; GO:0047298; GO:0048148; GO:0051536; GO:0070062; GO:0070474; GO:0090331; GO:0097151; GO:1902722; GO:1904450	0	0	cd00610;	PF00202;	1129	m.42242	74657.5	35315.5	148047	192209.3333	141378	163856	251433	299161.5	85572	268028.5	1.805337662
CHOYP_CAN5.1.1	P80404	m.42243	sp	GABT_HUMAN	51.02	490	231	2	20	500	9	498	0	534	GABT_HUMAN	reviewed	"4-aminobutyrate aminotransferase, mitochondrial (EC 2.6.1.19) ((S)-3-amino-2-methylpropionate transaminase) (EC 2.6.1.22) (GABA aminotransferase) (GABA-AT) (Gamma-amino-N-butyrate transaminase) (GABA transaminase) (GABA-T) (L-AIBAT)"	ABAT GABAT	Homo sapiens (Human)	500	aging [GO:0007568]; behavioral response to cocaine [GO:0048148]; cerebellum development [GO:0021549]; copulation [GO:0007620]; exploration behavior [GO:0035640]; gamma-aminobutyric acid biosynthetic process [GO:0009449]; gamma-aminobutyric acid catabolic process [GO:0009450]; locomotory behavior [GO:0007626]; negative regulation of blood pressure [GO:0045776]; negative regulation of dopamine secretion [GO:0033602]; negative regulation of gamma-aminobutyric acid secretion [GO:0014053]; negative regulation of platelet aggregation [GO:0090331]; neurotransmitter catabolic process [GO:0042135]; positive regulation of aspartate secretion [GO:1904450]; positive regulation of dopamine metabolic process [GO:0045964]; positive regulation of heat generation [GO:0031652]; positive regulation of inhibitory postsynaptic potential [GO:0097151]; positive regulation of insulin secretion [GO:0032024]; positive regulation of prolactin secretion [GO:1902722]; positive regulation of uterine smooth muscle contraction [GO:0070474]; response to drug [GO:0042493]; response to ethanol [GO:0045471]; response to hypoxia [GO:0001666]; response to iron ion [GO:0010039]; response to nicotine [GO:0035094]	GO:0001666; GO:0003867; GO:0005739; GO:0005759; GO:0007568; GO:0007620; GO:0007626; GO:0009449; GO:0009450; GO:0010039; GO:0014053; GO:0021549; GO:0030170; GO:0031652; GO:0032024; GO:0032144; GO:0032145; GO:0033602; GO:0035094; GO:0035640; GO:0042135; GO:0042493; GO:0042803; GO:0043005; GO:0045471; GO:0045776; GO:0045964; GO:0046872; GO:0047298; GO:0048148; GO:0051536; GO:0070062; GO:0070474; GO:0090331; GO:0097151; GO:1902722; GO:1904450	0	0	cd00610;	PF00202;	1130	m.42243	583881	286334.6667	78863.5	517564.4	49633.25	1178034.5	721463.6667	1482240.5	543327.3333	3179202.4	4.685337349
CHOYP_CATA.2.3	P04040	m.18454	sp	CATA_HUMAN	75.811	339	80	1	3	339	4	342	0	542	CATA_HUMAN	reviewed	Catalase (EC 1.11.1.6)	CAT	Homo sapiens (Human)	527	aerobic respiration [GO:0009060]; aging [GO:0007568]; cellular response to growth factor stimulus [GO:0071363]; cholesterol metabolic process [GO:0008203]; hemoglobin metabolic process [GO:0020027]; hydrogen peroxide catabolic process [GO:0042744]; negative regulation of apoptotic process [GO:0043066]; negative regulation of NF-kappaB transcription factor activity [GO:0032088]; osteoblast differentiation [GO:0001649]; positive regulation of cell division [GO:0051781]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of phosphatidylinositol 3-kinase signaling [GO:0014068]; protein homotetramerization [GO:0051289]; protein tetramerization [GO:0051262]; purine nucleotide catabolic process [GO:0006195]; response to activity [GO:0014823]; response to cadmium ion [GO:0046686]; response to drug [GO:0042493]; response to estradiol [GO:0032355]; response to ethanol [GO:0045471]; response to fatty acid [GO:0070542]; response to hydrogen peroxide [GO:0042542]; response to hyperoxia [GO:0055093]; response to hypoxia [GO:0001666]; response to inactivity [GO:0014854]; response to insulin [GO:0032868]; response to L-ascorbic acid [GO:0033591]; response to lead ion [GO:0010288]; response to light intensity [GO:0009642]; response to ozone [GO:0010193]; response to phenylpropanoid [GO:0080184]; response to reactive oxygen species [GO:0000302]; response to vitamin A [GO:0033189]; response to vitamin E [GO:0033197]; triglyceride metabolic process [GO:0006641]; ureteric bud development [GO:0001657]; UV protection [GO:0009650]	GO:0000302; GO:0001649; GO:0001657; GO:0001666; GO:0004046; GO:0004096; GO:0005102; GO:0005615; GO:0005739; GO:0005758; GO:0005764; GO:0005777; GO:0005778; GO:0005782; GO:0005783; GO:0005794; GO:0005829; GO:0005886; GO:0005925; GO:0006195; GO:0006641; GO:0007568; GO:0008203; GO:0009060; GO:0009642; GO:0009650; GO:0010193; GO:0010288; GO:0014068; GO:0014823; GO:0014854; GO:0016020; GO:0016209; GO:0016684; GO:0019899; GO:0020027; GO:0020037; GO:0032088; GO:0032355; GO:0032868; GO:0033189; GO:0033197; GO:0033591; GO:0042493; GO:0042542; GO:0042744; GO:0042803; GO:0043066; GO:0043231; GO:0045471; GO:0046686; GO:0046872; GO:0050661; GO:0051092; GO:0051262; GO:0051289; GO:0051781; GO:0055093; GO:0070062; GO:0070542; GO:0071363; GO:0080184	0	0	0	PF00199;PF06628;	1165	m.18454	564396.7647	367283.6364	705840.0714	416959.6667	404097.5455	522593.3125	440098.7778	395214.6923	1367748.25	818153.3125	1.441405886
CHOYP_CATA.2.3	P04040	m.18454	sp	CATA_HUMAN	75.811	339	80	1	3	339	4	342	0	542	CATA_HUMAN	reviewed	Catalase (EC 1.11.1.6)	CAT	Homo sapiens (Human)	527	aerobic respiration [GO:0009060]; aging [GO:0007568]; cellular response to growth factor stimulus [GO:0071363]; cholesterol metabolic process [GO:0008203]; hemoglobin metabolic process [GO:0020027]; hydrogen peroxide catabolic process [GO:0042744]; negative regulation of apoptotic process [GO:0043066]; negative regulation of NF-kappaB transcription factor activity [GO:0032088]; osteoblast differentiation [GO:0001649]; positive regulation of cell division [GO:0051781]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of phosphatidylinositol 3-kinase signaling [GO:0014068]; protein homotetramerization [GO:0051289]; protein tetramerization [GO:0051262]; purine nucleotide catabolic process [GO:0006195]; response to activity [GO:0014823]; response to cadmium ion [GO:0046686]; response to drug [GO:0042493]; response to estradiol [GO:0032355]; response to ethanol [GO:0045471]; response to fatty acid [GO:0070542]; response to hydrogen peroxide [GO:0042542]; response to hyperoxia [GO:0055093]; response to hypoxia [GO:0001666]; response to inactivity [GO:0014854]; response to insulin [GO:0032868]; response to L-ascorbic acid [GO:0033591]; response to lead ion [GO:0010288]; response to light intensity [GO:0009642]; response to ozone [GO:0010193]; response to phenylpropanoid [GO:0080184]; response to reactive oxygen species [GO:0000302]; response to vitamin A [GO:0033189]; response to vitamin E [GO:0033197]; triglyceride metabolic process [GO:0006641]; ureteric bud development [GO:0001657]; UV protection [GO:0009650]	GO:0000302; GO:0001649; GO:0001657; GO:0001666; GO:0004046; GO:0004096; GO:0005102; GO:0005615; GO:0005739; GO:0005758; GO:0005764; GO:0005777; GO:0005778; GO:0005782; GO:0005783; GO:0005794; GO:0005829; GO:0005886; GO:0005925; GO:0006195; GO:0006641; GO:0007568; GO:0008203; GO:0009060; GO:0009642; GO:0009650; GO:0010193; GO:0010288; GO:0014068; GO:0014823; GO:0014854; GO:0016020; GO:0016209; GO:0016684; GO:0019899; GO:0020027; GO:0020037; GO:0032088; GO:0032355; GO:0032868; GO:0033189; GO:0033197; GO:0033591; GO:0042493; GO:0042542; GO:0042744; GO:0042803; GO:0043066; GO:0043231; GO:0045471; GO:0046686; GO:0046872; GO:0050661; GO:0051092; GO:0051262; GO:0051289; GO:0051781; GO:0055093; GO:0070062; GO:0070542; GO:0071363; GO:0080184	0	0	0	PF00199;PF06628;	1166	m.18456	59230.66667	218247.6667	549006.5	1407834.8	2466046.5	1077172.333	152714.6667	51178	83431	301492.6667	0.354438063
CHOYP_CBS.1.2	Q91WT9	m.54537	sp	CBS_MOUSE	61.914	533	179	4	15	533	38	560	0	694	CBS_MOUSE	reviewed	Cystathionine beta-synthase (EC 4.2.1.22) (Beta-thionase) (Serine sulfhydrase)	Cbs	Mus musculus (Mouse)	561	blood vessel remodeling [GO:0001974]; cartilage development involved in endochondral bone morphogenesis [GO:0060351]; cellular amino acid biosynthetic process [GO:0008652]; cellular response to hypoxia [GO:0071456]; cerebellum morphogenesis [GO:0021587]; cysteine biosynthetic process [GO:0019344]; cysteine biosynthetic process from serine [GO:0006535]; cysteine biosynthetic process via cystathionine [GO:0019343]; endochondral ossification [GO:0001958]; homocysteine catabolic process [GO:0043418]; homocysteine metabolic process [GO:0050667]; hydrogen sulfide biosynthetic process [GO:0070814]; L-serine metabolic process [GO:0006563]; maternal process involved in female pregnancy [GO:0060135]; negative regulation of apoptotic process [GO:0043066]; regulation of blood vessel size [GO:0050880]; regulation of cGMP metabolic process [GO:0030823]; regulation of JUN kinase activity [GO:0043506]; response to folic acid [GO:0051593]; superoxide metabolic process [GO:0006801]; transsulfuration [GO:0019346]	GO:0001958; GO:0001974; GO:0004122; GO:0004124; GO:0005634; GO:0005737; GO:0005829; GO:0006535; GO:0006563; GO:0006801; GO:0008652; GO:0019343; GO:0019344; GO:0019346; GO:0019825; GO:0019899; GO:0020037; GO:0021587; GO:0030170; GO:0030823; GO:0031625; GO:0042802; GO:0042803; GO:0043066; GO:0043418; GO:0043506; GO:0046872; GO:0050421; GO:0050667; GO:0050880; GO:0051593; GO:0060135; GO:0060351; GO:0070025; GO:0070026; GO:0070814; GO:0071456; GO:0072341; GO:1904047	PATHWAY: Amino-acid biosynthesis; L-cysteine biosynthesis; L-cysteine from L-homocysteine and L-serine: step 1/2. {ECO:0000250|UniProtKB:P35520}.	0	0	PF00571;PF00291;	1180	m.54537	230001	130461	790066	188393.375	69926.71429	555846.4444	455478.5714	1875206.545	1146142	490528.7778	3.21056782
CHOYP_CBS.2.2	Q91WT9	m.65898	sp	CBS_MOUSE	61.914	533	179	4	15	533	38	560	0	694	CBS_MOUSE	reviewed	Cystathionine beta-synthase (EC 4.2.1.22) (Beta-thionase) (Serine sulfhydrase)	Cbs	Mus musculus (Mouse)	561	blood vessel remodeling [GO:0001974]; cartilage development involved in endochondral bone morphogenesis [GO:0060351]; cellular amino acid biosynthetic process [GO:0008652]; cellular response to hypoxia [GO:0071456]; cerebellum morphogenesis [GO:0021587]; cysteine biosynthetic process [GO:0019344]; cysteine biosynthetic process from serine [GO:0006535]; cysteine biosynthetic process via cystathionine [GO:0019343]; endochondral ossification [GO:0001958]; homocysteine catabolic process [GO:0043418]; homocysteine metabolic process [GO:0050667]; hydrogen sulfide biosynthetic process [GO:0070814]; L-serine metabolic process [GO:0006563]; maternal process involved in female pregnancy [GO:0060135]; negative regulation of apoptotic process [GO:0043066]; regulation of blood vessel size [GO:0050880]; regulation of cGMP metabolic process [GO:0030823]; regulation of JUN kinase activity [GO:0043506]; response to folic acid [GO:0051593]; superoxide metabolic process [GO:0006801]; transsulfuration [GO:0019346]	GO:0001958; GO:0001974; GO:0004122; GO:0004124; GO:0005634; GO:0005737; GO:0005829; GO:0006535; GO:0006563; GO:0006801; GO:0008652; GO:0019343; GO:0019344; GO:0019346; GO:0019825; GO:0019899; GO:0020037; GO:0021587; GO:0030170; GO:0030823; GO:0031625; GO:0042802; GO:0042803; GO:0043066; GO:0043418; GO:0043506; GO:0046872; GO:0050421; GO:0050667; GO:0050880; GO:0051593; GO:0060135; GO:0060351; GO:0070025; GO:0070026; GO:0070814; GO:0071456; GO:0072341; GO:1904047	PATHWAY: Amino-acid biosynthesis; L-cysteine biosynthesis; L-cysteine from L-homocysteine and L-serine: step 1/2. {ECO:0000250|UniProtKB:P35520}.	0	0	PF00571;PF00291;	1181	m.65898	230001	130461	790066	188393.375	69926.71429	555846.4444	455478.5714	1875206.545	1146142	490528.7778	3.21056782
CHOYP_COX1.11.15	O09164	m.50553	sp	SODE_MOUSE	26.415	159	99	5	4	148	75	229	1.09E-08	55.5	SODE_MOUSE	reviewed	Extracellular superoxide dismutase [Cu-Zn] (EC-SOD) (EC 1.15.1.1)	Sod3	Mus musculus (Mouse)	251	response to copper ion [GO:0046688]; response to hypoxia [GO:0001666]; response to reactive oxygen species [GO:0000302]	GO:0000302; GO:0001666; GO:0004784; GO:0005507; GO:0005615; GO:0005634; GO:0005796; GO:0005802; GO:0008270; GO:0031012; GO:0046688; GO:0070062	0	0	cd00305;	PF00080;	1712	m.50553	149280	145904.5	715463.6	294631.5	178660.6667	579099.6667	494118	846515.83	402935	452613.6	1.870211463
CHOYP_CYT5.1.1	P14841	m.29962	sp	CYTC_RAT	30.208	96	63	2	3	95	35	129	9.33E-06	44.7	CYTC_RAT	reviewed	Cystatin-C (Cystatin-3)	Cst3	Rattus norvegicus (Rat)	140	"apoptotic process [GO:0006915]; brain development [GO:0007420]; cell activation [GO:0001775]; cellular response to hydrogen peroxide [GO:0070301]; cellular response to oxidative stress [GO:0034599]; circadian sleep/wake cycle, REM sleep [GO:0042747]; embryo implantation [GO:0007566]; eye development [GO:0001654]; male gonad development [GO:0008584]; negative regulation of cell death [GO:0060548]; positive regulation of cell proliferation [GO:0008284]; positive regulation of DNA replication [GO:0045740]; regulation of programmed cell death [GO:0043067]; response to axon injury [GO:0048678]; response to carbohydrate [GO:0009743]; response to drug [GO:0042493]; response to estradiol [GO:0032355]; response to hypoxia [GO:0001666]; response to inorganic substance [GO:0010035]; response to nutrient levels [GO:0031667]; response to organic cyclic compound [GO:0014070]; response to oxidative stress [GO:0006979]; response to toxic substance [GO:0009636]; salivary gland development [GO:0007431]; Sertoli cell development [GO:0060009]"	GO:0001654; GO:0001666; GO:0001775; GO:0002020; GO:0004869; GO:0005604; GO:0005615; GO:0005737; GO:0005764; GO:0005771; GO:0005783; GO:0006915; GO:0006979; GO:0007420; GO:0007431; GO:0007566; GO:0008284; GO:0008584; GO:0009636; GO:0009743; GO:0010035; GO:0014070; GO:0030414; GO:0030424; GO:0031667; GO:0031965; GO:0031982; GO:0032355; GO:0034599; GO:0042493; GO:0042747; GO:0042995; GO:0043025; GO:0043067; GO:0043292; GO:0045740; GO:0048471; GO:0048678; GO:0060009; GO:0060548; GO:0070301	0	0	0	PF00031;	1802	m.29960	66898.8	126269.5	64611	712184.25	326682.45	417565.75	530142	295340.6667	1428826.833	764116	2.649906952
CHOYP_CYT5.1.1	P14841	m.29962	sp	CYTC_RAT	30.208	96	63	2	3	95	35	129	9.33E-06	44.7	CYTC_RAT	reviewed	Cystatin-C (Cystatin-3)	Cst3	Rattus norvegicus (Rat)	140	"apoptotic process [GO:0006915]; brain development [GO:0007420]; cell activation [GO:0001775]; cellular response to hydrogen peroxide [GO:0070301]; cellular response to oxidative stress [GO:0034599]; circadian sleep/wake cycle, REM sleep [GO:0042747]; embryo implantation [GO:0007566]; eye development [GO:0001654]; male gonad development [GO:0008584]; negative regulation of cell death [GO:0060548]; positive regulation of cell proliferation [GO:0008284]; positive regulation of DNA replication [GO:0045740]; regulation of programmed cell death [GO:0043067]; response to axon injury [GO:0048678]; response to carbohydrate [GO:0009743]; response to drug [GO:0042493]; response to estradiol [GO:0032355]; response to hypoxia [GO:0001666]; response to inorganic substance [GO:0010035]; response to nutrient levels [GO:0031667]; response to organic cyclic compound [GO:0014070]; response to oxidative stress [GO:0006979]; response to toxic substance [GO:0009636]; salivary gland development [GO:0007431]; Sertoli cell development [GO:0060009]"	GO:0001654; GO:0001666; GO:0001775; GO:0002020; GO:0004869; GO:0005604; GO:0005615; GO:0005737; GO:0005764; GO:0005771; GO:0005783; GO:0006915; GO:0006979; GO:0007420; GO:0007431; GO:0007566; GO:0008284; GO:0008584; GO:0009636; GO:0009743; GO:0010035; GO:0014070; GO:0030414; GO:0030424; GO:0031667; GO:0031965; GO:0031982; GO:0032355; GO:0034599; GO:0042493; GO:0042747; GO:0042995; GO:0043025; GO:0043067; GO:0043292; GO:0045740; GO:0048471; GO:0048678; GO:0060009; GO:0060548; GO:0070301	0	0	0	PF00031;	1803	m.29962	183189	92815	172106	157191	244696	60465	108336	236467	107114	716706.5	1.445991574
CHOYP_DPSE_GA11443.1.1	Q9U4L6	m.19526	sp	TO401_DROME	49.833	299	142	4	55	352	53	344	2.04E-104	313	TO401_DROME	reviewed	Mitochondrial import receptor subunit TOM40 homolog 1 (dtom40) (Male sterile protein 15) (Translocase of outer membrane 40 kDa subunit homolog 1)	Tom40 mit ms(1)15 CG12157	Drosophila melanogaster (Fruit fly)	344	cellular response to hypoxia [GO:0071456]; ion transport [GO:0006811]; protein import into mitochondrial matrix [GO:0030150]; protein targeting to mitochondrion [GO:0006626]	GO:0005739; GO:0005742; GO:0006626; GO:0006811; GO:0015266; GO:0015288; GO:0030150; GO:0046930; GO:0071456	0	0	0	PF01459;	1908	m.19526	1401114.25	241253.5	377447.5	193326	563989.5	1195056	1261477	19644	79405	297135.5	1.02721757
CHOYP_EF2.1.5	P24156	m.1541	sp	L2CC_DROME	72.862	269	73	0	2	270	3	271	1.06E-144	409	L2CC_DROME	reviewed	Protein l(2)37Cc	l(2)37Cc CG10691	Drosophila melanogaster (Fruit fly)	276	cellular response to hypoxia [GO:0071456]; multicellular organism development [GO:0007275]; sensory perception of pain [GO:0019233]	GO:0005737; GO:0005739; GO:0005811; GO:0005875; GO:0007275; GO:0016020; GO:0019233; GO:0071456	0	0	cd03401;	PF01145;	2032	m.1541	380779.125	332698.5	320094.5	290032.3889	565916.7059	554749.6429	317616.7222	147127	2198618.13	1472334.462	2.482346273
CHOYP_EF2.1.5	P24156	m.1541	sp	L2CC_DROME	72.862	269	73	0	2	270	3	271	1.06E-144	409	L2CC_DROME	reviewed	Protein l(2)37Cc	l(2)37Cc CG10691	Drosophila melanogaster (Fruit fly)	276	cellular response to hypoxia [GO:0071456]; multicellular organism development [GO:0007275]; sensory perception of pain [GO:0019233]	GO:0005737; GO:0005739; GO:0005811; GO:0005875; GO:0007275; GO:0016020; GO:0019233; GO:0071456	0	0	cd03401;	PF01145;	2033	m.1543	2525045.667	2820363.75	1828660.75	2221009	1223835.75	1186804.4	44781.5	756381.4	2085663.25	332933.3333	0.414973085
CHOYP_EF2.1.5	P24156	m.1541	sp	L2CC_DROME	72.862	269	73	0	2	270	3	271	1.06E-144	409	L2CC_DROME	reviewed	Protein l(2)37Cc	l(2)37Cc CG10691	Drosophila melanogaster (Fruit fly)	276	cellular response to hypoxia [GO:0071456]; multicellular organism development [GO:0007275]; sensory perception of pain [GO:0019233]	GO:0005737; GO:0005739; GO:0005811; GO:0005875; GO:0007275; GO:0016020; GO:0019233; GO:0071456	0	0	cd03401;	PF01145;	2034	m.1544	4463160.8	1394922.833	258533	4251193.778	354542.75	3365192.167	491604.2	184927	1271099.6	199636.4286	0.514109106
CHOYP_EF2.1.5	P24156	m.1541	sp	L2CC_DROME	72.862	269	73	0	2	270	3	271	1.06E-144	409	L2CC_DROME	reviewed	Protein l(2)37Cc	l(2)37Cc CG10691	Drosophila melanogaster (Fruit fly)	276	cellular response to hypoxia [GO:0071456]; multicellular organism development [GO:0007275]; sensory perception of pain [GO:0019233]	GO:0005737; GO:0005739; GO:0005811; GO:0005875; GO:0007275; GO:0016020; GO:0019233; GO:0071456	0	0	cd03401;	PF01145;	2035	m.1547	18049	20701	25258	50015	18174	46594	1160889	14681	140007	472885	13.88122272
CHOYP_HIF1N.1.1	Q9NWT6	m.53726	sp	HIF1N_HUMAN	57.862	318	131	2	20	334	32	349	5.70E-137	395	HIF1N_HUMAN	reviewed	Hypoxia-inducible factor 1-alpha inhibitor (EC 1.14.11.30) (EC 1.14.11.n4) (Factor inhibiting HIF-1) (FIH-1) (Hypoxia-inducible factor asparagine hydroxylase)	HIF1AN FIH1	Homo sapiens (Human)	349	"negative regulation of Notch signaling pathway [GO:0045746]; negative regulation of transcription from RNA polymerase II promoter in response to hypoxia [GO:0061428]; oxidation-reduction process [GO:0055114]; peptidyl-asparagine hydroxylation [GO:0042265]; peptidyl-aspartic acid hydroxylation [GO:0042264]; peptidyl-histidine hydroxylation [GO:0036138]; positive regulation of myoblast differentiation [GO:0045663]; positive regulation of vasculogenesis [GO:2001214]; regulation of transcription from RNA polymerase II promoter in response to hypoxia [GO:0061418]; transcription, DNA-templated [GO:0006351]"	GO:0005112; GO:0005506; GO:0005654; GO:0005737; GO:0005829; GO:0006351; GO:0008270; GO:0016706; GO:0019826; GO:0031406; GO:0036138; GO:0036139; GO:0036140; GO:0042264; GO:0042265; GO:0042803; GO:0045663; GO:0045746; GO:0048037; GO:0048471; GO:0051059; GO:0055114; GO:0061418; GO:0061428; GO:0071532; GO:2001214	0	0	0	0	2308	m.53726	612515.3333	243687	430203	376234	55783.5	190163	3444005	269370	1140837.333	394423	3.164994219
CHOYP_HYOU1.3.3	Q9Y4L1	m.28442	sp	HYOU1_HUMAN	43.75	208	108	3	2	207	739	939	5.24E-41	154	HYOU1_HUMAN	reviewed	Hypoxia up-regulated protein 1 (150 kDa oxygen-regulated protein) (ORP-150) (170 kDa glucose-regulated protein) (GRP-170)	HYOU1 GRP170 ORP150	Homo sapiens (Human)	999	cellular response to hypoxia [GO:0071456]; ER to Golgi vesicle-mediated transport [GO:0006888]; IRE1-mediated unfolded protein response [GO:0036498]; negative regulation of endoplasmic reticulum stress-induced neuron intrinsic apoptotic signaling pathway [GO:1903382]; negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway [GO:1903298]; receptor-mediated endocytosis [GO:0006898]; response to endoplasmic reticulum stress [GO:0034976]; response to ischemia [GO:0002931]	GO:0002931; GO:0005524; GO:0005576; GO:0005783; GO:0005788; GO:0005790; GO:0005925; GO:0006888; GO:0006898; GO:0016020; GO:0034663; GO:0034976; GO:0036498; GO:0051087; GO:0070062; GO:0071456; GO:0071682; GO:1903298; GO:1903382	0	0	0	PF00012;	2406	m.28442	349834.6667	186919	5250015.75	857059	43037	349373.6667	765713.5	458386	121379.3333	39706.5	0.259397923
CHOYP_ISCW_ISCW012366.1.1	P53563	m.3690	sp	B2CL1_RAT	30.921	152	96	3	130	273	82	232	7.48E-17	80.9	B2CL1_RAT	reviewed	Bcl-2-like protein 1 (Bcl2-L-1) (Apoptosis regulator Bcl-X)	Bcl2l1 Bclx Blc2l	Rattus norvegicus (Rat)	233	aging [GO:0007568]; apoptotic process [GO:0006915]; cerebral cortex development [GO:0021987]; cytokinesis [GO:0000910]; endocytosis [GO:0006897]; extrinsic apoptotic signaling pathway in absence of ligand [GO:0097192]; intrinsic apoptotic signaling pathway in response to DNA damage [GO:0008630]; mitotic cell cycle checkpoint [GO:0007093]; negative regulation of apoptotic process [GO:0043066]; negative regulation of intrinsic apoptotic signaling pathway [GO:2001243]; ovarian follicle development [GO:0001541]; regulation of apoptotic process [GO:0042981]; response to electrical stimulus [GO:0051602]; response to hydrogen peroxide [GO:0042542]; response to hypoxia [GO:0001666]; response to inorganic substance [GO:0010035]; response to ischemia [GO:0002931]; response to lead ion [GO:0010288]; response to organic cyclic compound [GO:0014070]; response to organonitrogen compound [GO:0010243]; response to oxidative stress [GO:0006979]; response to peptide hormone [GO:0043434]	GO:0000910; GO:0001541; GO:0001666; GO:0002931; GO:0005739; GO:0005740; GO:0005741; GO:0005743; GO:0005759; GO:0005813; GO:0005829; GO:0006897; GO:0006915; GO:0006979; GO:0007093; GO:0007568; GO:0008630; GO:0010035; GO:0010243; GO:0010288; GO:0014070; GO:0016021; GO:0021987; GO:0030054; GO:0030672; GO:0031965; GO:0042542; GO:0042803; GO:0042981; GO:0043027; GO:0043066; GO:0043434; GO:0046982; GO:0051400; GO:0051602; GO:0097192; GO:0097371; GO:2001243	0	0	0	PF00452;PF02180;	2495	m.3691	5954836.833	449406	266357.1667	375873	197061.8334	206763.75	2988434.8	1828123.5	183205.75	485289.75	0.785778999
CHOYP_ISCW_ISCW012366.1.1	P53563	m.3692	sp	B2CL1_RAT	30.921	152	96	3	115	258	82	232	7.30E-17	80.5	B2CL1_RAT	reviewed	Bcl-2-like protein 1 (Bcl2-L-1) (Apoptosis regulator Bcl-X)	Bcl2l1 Bclx Blc2l	Rattus norvegicus (Rat)	233	aging [GO:0007568]; apoptotic process [GO:0006915]; cerebral cortex development [GO:0021987]; cytokinesis [GO:0000910]; endocytosis [GO:0006897]; extrinsic apoptotic signaling pathway in absence of ligand [GO:0097192]; intrinsic apoptotic signaling pathway in response to DNA damage [GO:0008630]; mitotic cell cycle checkpoint [GO:0007093]; negative regulation of apoptotic process [GO:0043066]; negative regulation of intrinsic apoptotic signaling pathway [GO:2001243]; ovarian follicle development [GO:0001541]; regulation of apoptotic process [GO:0042981]; response to electrical stimulus [GO:0051602]; response to hydrogen peroxide [GO:0042542]; response to hypoxia [GO:0001666]; response to inorganic substance [GO:0010035]; response to ischemia [GO:0002931]; response to lead ion [GO:0010288]; response to organic cyclic compound [GO:0014070]; response to organonitrogen compound [GO:0010243]; response to oxidative stress [GO:0006979]; response to peptide hormone [GO:0043434]	GO:0000910; GO:0001541; GO:0001666; GO:0002931; GO:0005739; GO:0005740; GO:0005741; GO:0005743; GO:0005759; GO:0005813; GO:0005829; GO:0006897; GO:0006915; GO:0006979; GO:0007093; GO:0007568; GO:0008630; GO:0010035; GO:0010243; GO:0010288; GO:0014070; GO:0016021; GO:0021987; GO:0030054; GO:0030672; GO:0031965; GO:0042542; GO:0042803; GO:0042981; GO:0043027; GO:0043066; GO:0043434; GO:0046982; GO:0051400; GO:0051602; GO:0097192; GO:0097371; GO:2001243	0	0	0	PF00452;PF02180;	2495	m.3691	5954836.833	449406	266357.1667	375873	197061.8334	206763.75	2988434.8	1828123.5	183205.75	485289.75	0.785778999
CHOYP_KPYK.3.4	P14618	m.47446	sp	KPYM_HUMAN	68.632	424	129	1	62	481	9	432	0	607	KPYM_HUMAN	reviewed	Pyruvate kinase PKM (EC 2.7.1.40) (Cytosolic thyroid hormone-binding protein) (CTHBP) (Opa-interacting protein 3) (OIP-3) (Pyruvate kinase 2/3) (Pyruvate kinase muscle isozyme) (Thyroid hormone-binding protein 1) (THBP1) (Tumor M2-PK) (p58)	PKM OIP3 PK2 PK3 PKM2	Homo sapiens (Human)	531	ATP biosynthetic process [GO:0006754]; canonical glycolysis [GO:0061621]; liver development [GO:0001889]; organ regeneration [GO:0031100]; programmed cell death [GO:0012501]; pyruvate biosynthetic process [GO:0042866]; response to gravity [GO:0009629]; response to hypoxia [GO:0001666]; response to insulin [GO:0032868]; response to muscle inactivity [GO:0014870]; response to nutrient [GO:0007584]; skeletal muscle tissue regeneration [GO:0043403]	GO:0000287; GO:0001666; GO:0001889; GO:0004743; GO:0005524; GO:0005634; GO:0005737; GO:0005739; GO:0005829; GO:0005886; GO:0005913; GO:0005929; GO:0006754; GO:0007584; GO:0009629; GO:0012501; GO:0014870; GO:0016301; GO:0023026; GO:0030955; GO:0031012; GO:0031100; GO:0031982; GO:0032868; GO:0042866; GO:0043209; GO:0043403; GO:0043531; GO:0044822; GO:0061621; GO:0070062; GO:0098641; GO:1903561	PATHWAY: Carbohydrate degradation; glycolysis; pyruvate from D-glyceraldehyde 3-phosphate: step 5/5.	0	0	PF00224;PF02887;	2645	m.47446	425284.8333	170048.6667	69892.75	2214681.667	640517	529533.8	510257.3333	107230	3506885.875	566484.0512	1.482886635
CHOYP_KPYK.4.4	P14618	m.48513	sp	KPYM_HUMAN	67.76	366	118	0	9	374	166	531	0	527	KPYM_HUMAN	reviewed	Pyruvate kinase PKM (EC 2.7.1.40) (Cytosolic thyroid hormone-binding protein) (CTHBP) (Opa-interacting protein 3) (OIP-3) (Pyruvate kinase 2/3) (Pyruvate kinase muscle isozyme) (Thyroid hormone-binding protein 1) (THBP1) (Tumor M2-PK) (p58)	PKM OIP3 PK2 PK3 PKM2	Homo sapiens (Human)	531	ATP biosynthetic process [GO:0006754]; canonical glycolysis [GO:0061621]; liver development [GO:0001889]; organ regeneration [GO:0031100]; programmed cell death [GO:0012501]; pyruvate biosynthetic process [GO:0042866]; response to gravity [GO:0009629]; response to hypoxia [GO:0001666]; response to insulin [GO:0032868]; response to muscle inactivity [GO:0014870]; response to nutrient [GO:0007584]; skeletal muscle tissue regeneration [GO:0043403]	GO:0000287; GO:0001666; GO:0001889; GO:0004743; GO:0005524; GO:0005634; GO:0005737; GO:0005739; GO:0005829; GO:0005886; GO:0005913; GO:0005929; GO:0006754; GO:0007584; GO:0009629; GO:0012501; GO:0014870; GO:0016301; GO:0023026; GO:0030955; GO:0031012; GO:0031100; GO:0031982; GO:0032868; GO:0042866; GO:0043209; GO:0043403; GO:0043531; GO:0044822; GO:0061621; GO:0070062; GO:0098641; GO:1903561	PATHWAY: Carbohydrate degradation; glycolysis; pyruvate from D-glyceraldehyde 3-phosphate: step 5/5.	0	0	PF00224;PF02887;	2646	m.48513	425284.8333	61156.2	69892.75	2392403.429	640517	529533.8	510257.3333	107230	3820747.714	566484.0512	1.541894937
CHOYP_KPYK.4.4	P14618	m.48513	sp	KPYM_HUMAN	67.76	366	118	0	9	374	166	531	0	527	KPYM_HUMAN	reviewed	Pyruvate kinase PKM (EC 2.7.1.40) (Cytosolic thyroid hormone-binding protein) (CTHBP) (Opa-interacting protein 3) (OIP-3) (Pyruvate kinase 2/3) (Pyruvate kinase muscle isozyme) (Thyroid hormone-binding protein 1) (THBP1) (Tumor M2-PK) (p58)	PKM OIP3 PK2 PK3 PKM2	Homo sapiens (Human)	531	ATP biosynthetic process [GO:0006754]; canonical glycolysis [GO:0061621]; liver development [GO:0001889]; organ regeneration [GO:0031100]; programmed cell death [GO:0012501]; pyruvate biosynthetic process [GO:0042866]; response to gravity [GO:0009629]; response to hypoxia [GO:0001666]; response to insulin [GO:0032868]; response to muscle inactivity [GO:0014870]; response to nutrient [GO:0007584]; skeletal muscle tissue regeneration [GO:0043403]	GO:0000287; GO:0001666; GO:0001889; GO:0004743; GO:0005524; GO:0005634; GO:0005737; GO:0005739; GO:0005829; GO:0005886; GO:0005913; GO:0005929; GO:0006754; GO:0007584; GO:0009629; GO:0012501; GO:0014870; GO:0016301; GO:0023026; GO:0030955; GO:0031012; GO:0031100; GO:0031982; GO:0032868; GO:0042866; GO:0043209; GO:0043403; GO:0043531; GO:0044822; GO:0061621; GO:0070062; GO:0098641; GO:1903561	PATHWAY: Carbohydrate degradation; glycolysis; pyruvate from D-glyceraldehyde 3-phosphate: step 5/5.	0	0	PF00224;PF02887;	2647	m.48514	NA	714511	NA	1592655.5	NA	NA	NA	NA	1309853	499399.3333	0.784188022
CHOYP_KPYM.1.1	P14618	m.33498	sp	KPYM_HUMAN	66.923	520	168	1	22	537	9	528	0	730	KPYM_HUMAN	reviewed	Pyruvate kinase PKM (EC 2.7.1.40) (Cytosolic thyroid hormone-binding protein) (CTHBP) (Opa-interacting protein 3) (OIP-3) (Pyruvate kinase 2/3) (Pyruvate kinase muscle isozyme) (Thyroid hormone-binding protein 1) (THBP1) (Tumor M2-PK) (p58)	PKM OIP3 PK2 PK3 PKM2	Homo sapiens (Human)	531	ATP biosynthetic process [GO:0006754]; canonical glycolysis [GO:0061621]; liver development [GO:0001889]; organ regeneration [GO:0031100]; programmed cell death [GO:0012501]; pyruvate biosynthetic process [GO:0042866]; response to gravity [GO:0009629]; response to hypoxia [GO:0001666]; response to insulin [GO:0032868]; response to muscle inactivity [GO:0014870]; response to nutrient [GO:0007584]; skeletal muscle tissue regeneration [GO:0043403]	GO:0000287; GO:0001666; GO:0001889; GO:0004743; GO:0005524; GO:0005634; GO:0005737; GO:0005739; GO:0005829; GO:0005886; GO:0005913; GO:0005929; GO:0006754; GO:0007584; GO:0009629; GO:0012501; GO:0014870; GO:0016301; GO:0023026; GO:0030955; GO:0031012; GO:0031100; GO:0031982; GO:0032868; GO:0042866; GO:0043209; GO:0043403; GO:0043531; GO:0044822; GO:0061621; GO:0070062; GO:0098641; GO:1903561	PATHWAY: Carbohydrate degradation; glycolysis; pyruvate from D-glyceraldehyde 3-phosphate: step 5/5.	0	0	PF00224;PF02887;	2648	m.33498	326764.25	5826390.182	10333566.38	1555468.308	739136	2734932	674176.8	2126975	49709074.85	1494623.188	3.02107447
CHOYP_LOC100083074.1.1	Q08420	m.1592	sp	SODE_RAT	24.176	182	118	6	49	216	48	223	2.37E-09	58.9	SODE_RAT	reviewed	Extracellular superoxide dismutase [Cu-Zn] (EC-SOD) (EC 1.15.1.1) (Superoxide dismutase B)	Sod3 Sod-3	Rattus norvegicus (Rat)	244	response to copper ion [GO:0046688]; response to hypoxia [GO:0001666]; response to oxidative stress [GO:0006979]; response to superoxide [GO:0000303]	GO:0000303; GO:0001666; GO:0004784; GO:0005507; GO:0005615; GO:0005634; GO:0005737; GO:0005802; GO:0006979; GO:0008270; GO:0031012; GO:0046688; GO:0070062	0	0	cd00305;	PF00080;	2703	m.1592	149280	127898	715463.6	218126.3333	144283	501606.1429	376881.6667	846515.83	427851.1667	385176.1667	1.873015184
CHOYP_LOC100118291.1.1	Q5M824	m.54817	sp	SHC1_RAT	41.667	504	221	12	16	507	23	465	1.04E-110	340	SHC1_RAT	reviewed	SHC-transforming protein 1 (Src homology 2 domain-containing-transforming protein C1) (SH2 domain protein C1)	Shc1	Rattus norvegicus (Rat)	469	actin cytoskeleton organization [GO:0030036]; activation of MAPK activity [GO:0000187]; aging [GO:0007568]; angiogenesis [GO:0001525]; cellular response to growth factor stimulus [GO:0071363]; cellular response to insulin stimulus [GO:0032869]; epidermal growth factor receptor signaling pathway [GO:0007173]; insulin receptor signaling pathway [GO:0008286]; intracellular signal transduction [GO:0035556]; neuron differentiation [GO:0030182]; neuron projection development [GO:0031175]; organ regeneration [GO:0031100]; positive regulation of DNA replication [GO:0045740]; positive regulation of smooth muscle cell proliferation [GO:0048661]; positive regulation of vasoconstriction [GO:0045907]; regulation of growth [GO:0040008]; response to glucocorticoid [GO:0051384]; response to hydrogen peroxide [GO:0042542]; response to hypoxia [GO:0001666]; response to insulin [GO:0032868]; response to nicotine [GO:0035094]; response to organic cyclic compound [GO:0014070]; response to toxic substance [GO:0009636]	GO:0000187; GO:0001525; GO:0001666; GO:0001784; GO:0005154; GO:0005634; GO:0005737; GO:0005886; GO:0007173; GO:0007568; GO:0008286; GO:0009636; GO:0010008; GO:0014070; GO:0030036; GO:0030182; GO:0030971; GO:0031100; GO:0031175; GO:0032403; GO:0032868; GO:0032869; GO:0035094; GO:0035556; GO:0040008; GO:0042542; GO:0045740; GO:0045907; GO:0048661; GO:0051219; GO:0051384; GO:0051721; GO:0070435; GO:0071363	0	0	0	PF00640;PF00017;	2738	m.54817	488856.5	140357	192246	147014.5	287558	398520	348761.5	123589	36268.5	145902	0.838387079
CHOYP_LOC100118811.1.1	P97526	m.57633	sp	NF1_RAT	57.778	2925	1023	48	1	2818	1	2820	0	3225	NF1_RAT	reviewed	Neurofibromin (Neurofibromatosis-related protein NF-1)	Nf1	Rattus norvegicus (Rat)	2820	actin cytoskeleton organization [GO:0030036]; adrenal gland development [GO:0030325]; artery morphogenesis [GO:0048844]; brain development [GO:0007420]; camera-type eye morphogenesis [GO:0048593]; cell communication [GO:0007154]; cerebral cortex development [GO:0021987]; collagen fibril organization [GO:0030199]; extracellular matrix organization [GO:0030198]; forebrain astrocyte development [GO:0021897]; forebrain morphogenesis [GO:0048853]; heart development [GO:0007507]; liver development [GO:0001889]; MAPK cascade [GO:0000165]; metanephros development [GO:0001656]; myelination in peripheral nervous system [GO:0022011]; negative regulation of fibroblast proliferation [GO:0048147]; negative regulation of MAPK cascade [GO:0043409]; negative regulation of MAP kinase activity [GO:0043407]; negative regulation of neuroblast proliferation [GO:0007406]; negative regulation of oligodendrocyte differentiation [GO:0048715]; negative regulation of protein kinase activity [GO:0006469]; negative regulation of Ras protein signal transduction [GO:0046580]; negative regulation of transcription factor import into nucleus [GO:0042992]; osteoblast differentiation [GO:0001649]; peripheral nervous system development [GO:0007422]; phosphatidylinositol 3-kinase signaling [GO:0014065]; pigmentation [GO:0043473]; positive regulation of adenylate cyclase activity [GO:0045762]; positive regulation of apoptotic process [GO:0043065]; positive regulation of GTPase activity [GO:0043547]; positive regulation of neuron apoptotic process [GO:0043525]; Ras protein signal transduction [GO:0007265]; regulation of angiogenesis [GO:0045765]; regulation of bone resorption [GO:0045124]; regulation of cell-matrix adhesion [GO:0001952]; regulation of glial cell differentiation [GO:0045685]; regulation of GTPase activity [GO:0043087]; regulation of neuron differentiation [GO:0045664]; response to hypoxia [GO:0001666]; Schwann cell development [GO:0014044]; smooth muscle tissue development [GO:0048745]; spinal cord development [GO:0021510]; sympathetic nervous system development [GO:0048485]; visual learning [GO:0008542]; wound healing [GO:0042060]	GO:0000165; GO:0001649; GO:0001656; GO:0001666; GO:0001889; GO:0001952; GO:0005096; GO:0005634; GO:0005730; GO:0005737; GO:0006469; GO:0007154; GO:0007265; GO:0007406; GO:0007420; GO:0007422; GO:0007507; GO:0008017; GO:0008429; GO:0008542; GO:0014044; GO:0014065; GO:0014069; GO:0016020; GO:0021510; GO:0021897; GO:0021987; GO:0022011; GO:0030036; GO:0030198; GO:0030199; GO:0030325; GO:0030424; GO:0030425; GO:0031210; GO:0031235; GO:0042060; GO:0042992; GO:0043005; GO:0043065; GO:0043087; GO:0043234; GO:0043407; GO:0043409; GO:0043473; GO:0043525; GO:0043547; GO:0045124; GO:0045545; GO:0045664; GO:0045685; GO:0045762; GO:0045765; GO:0046580; GO:0048147; GO:0048485; GO:0048593; GO:0048715; GO:0048745; GO:0048844; GO:0048853	0	0	0	PF13716;PF00616;	2741	m.57633	81642	44884	57794	93490	35947	10058922	35835	90592	271639	74716	33.56643517
CHOYP_LOC100368666.1.1	P70549	m.43153	sp	NAC3_RAT	55.605	901	364	13	28	906	38	924	0	987	NAC3_RAT	reviewed	Sodium/calcium exchanger 3 (Na(+)/Ca(2+)-exchange protein 3) (Solute carrier family 8 member 3)	Slc8a3 Ncx3	Rattus norvegicus (Rat)	927	calcium ion export from cell [GO:1990034]; calcium ion import into cell [GO:1990035]; calcium ion transport into cytosol [GO:0060402]; cell communication [GO:0007154]; cellular response to cAMP [GO:0071320]; cellular response to hypoxia [GO:0071456]; hematopoietic progenitor cell differentiation [GO:0002244]; learning [GO:0007612]; long-term synaptic potentiation [GO:0060291]; memory [GO:0007613]; mitochondrial calcium ion homeostasis [GO:0051560]; mitochondrial calcium ion transport [GO:0006851]; myelination [GO:0042552]; oligodendrocyte differentiation [GO:0048709]; regulation of skeletal muscle contraction [GO:0014819]; sodium ion transport [GO:0006814]; telencephalon development [GO:0021537]	GO:0002244; GO:0005432; GO:0005739; GO:0005741; GO:0005789; GO:0005874; GO:0005886; GO:0005887; GO:0006814; GO:0006851; GO:0007154; GO:0007612; GO:0007613; GO:0014819; GO:0016528; GO:0021537; GO:0030054; GO:0031594; GO:0042383; GO:0042552; GO:0042995; GO:0043025; GO:0043197; GO:0043204; GO:0046872; GO:0048471; GO:0048709; GO:0051560; GO:0060291; GO:0060402; GO:0071320; GO:0071456; GO:1990034; GO:1990035	0	0	0	PF03160;PF01699;PF16494;	3077	m.43153	30266	20113	NA	58261	32071	282902.3333	95341.5	17187	337790.6667	51374	4.460748627
CHOYP_LOC100371005.1.2	P14618	m.2526	sp	KPYM_HUMAN	46.109	514	270	5	5	513	20	531	2.55E-158	464	KPYM_HUMAN	reviewed	Pyruvate kinase PKM (EC 2.7.1.40) (Cytosolic thyroid hormone-binding protein) (CTHBP) (Opa-interacting protein 3) (OIP-3) (Pyruvate kinase 2/3) (Pyruvate kinase muscle isozyme) (Thyroid hormone-binding protein 1) (THBP1) (Tumor M2-PK) (p58)	PKM OIP3 PK2 PK3 PKM2	Homo sapiens (Human)	531	ATP biosynthetic process [GO:0006754]; canonical glycolysis [GO:0061621]; liver development [GO:0001889]; organ regeneration [GO:0031100]; programmed cell death [GO:0012501]; pyruvate biosynthetic process [GO:0042866]; response to gravity [GO:0009629]; response to hypoxia [GO:0001666]; response to insulin [GO:0032868]; response to muscle inactivity [GO:0014870]; response to nutrient [GO:0007584]; skeletal muscle tissue regeneration [GO:0043403]	GO:0000287; GO:0001666; GO:0001889; GO:0004743; GO:0005524; GO:0005634; GO:0005737; GO:0005739; GO:0005829; GO:0005886; GO:0005913; GO:0005929; GO:0006754; GO:0007584; GO:0009629; GO:0012501; GO:0014870; GO:0016301; GO:0023026; GO:0030955; GO:0031012; GO:0031100; GO:0031982; GO:0032868; GO:0042866; GO:0043209; GO:0043403; GO:0043531; GO:0044822; GO:0061621; GO:0070062; GO:0098641; GO:1903561	PATHWAY: Carbohydrate degradation; glycolysis; pyruvate from D-glyceraldehyde 3-phosphate: step 5/5.	0	0	PF00224;PF02887;	3185	m.2526	7219678.167	1692610.167	2821816	8134157.5	5514680	10404759.2	3291401.833	1453337.6	3346412	252362	0.738617011
CHOYP_LOC100371005.1.2	P14618	m.2526	sp	KPYM_HUMAN	46.109	514	270	5	5	513	20	531	2.55E-158	464	KPYM_HUMAN	reviewed	Pyruvate kinase PKM (EC 2.7.1.40) (Cytosolic thyroid hormone-binding protein) (CTHBP) (Opa-interacting protein 3) (OIP-3) (Pyruvate kinase 2/3) (Pyruvate kinase muscle isozyme) (Thyroid hormone-binding protein 1) (THBP1) (Tumor M2-PK) (p58)	PKM OIP3 PK2 PK3 PKM2	Homo sapiens (Human)	531	ATP biosynthetic process [GO:0006754]; canonical glycolysis [GO:0061621]; liver development [GO:0001889]; organ regeneration [GO:0031100]; programmed cell death [GO:0012501]; pyruvate biosynthetic process [GO:0042866]; response to gravity [GO:0009629]; response to hypoxia [GO:0001666]; response to insulin [GO:0032868]; response to muscle inactivity [GO:0014870]; response to nutrient [GO:0007584]; skeletal muscle tissue regeneration [GO:0043403]	GO:0000287; GO:0001666; GO:0001889; GO:0004743; GO:0005524; GO:0005634; GO:0005737; GO:0005739; GO:0005829; GO:0005886; GO:0005913; GO:0005929; GO:0006754; GO:0007584; GO:0009629; GO:0012501; GO:0014870; GO:0016301; GO:0023026; GO:0030955; GO:0031012; GO:0031100; GO:0031982; GO:0032868; GO:0042866; GO:0043209; GO:0043403; GO:0043531; GO:0044822; GO:0061621; GO:0070062; GO:0098641; GO:1903561	PATHWAY: Carbohydrate degradation; glycolysis; pyruvate from D-glyceraldehyde 3-phosphate: step 5/5.	0	0	PF00224;PF02887;	3186	m.2527	137537.5	18366	39413	39137.5	33383	182343	31959.5	43705	98445.66667	200256.6667	2.078539684
CHOYP_LOC100371043.4.5	P00184	m.34262	sp	CP1A1_MOUSE	25.688	109	80	1	10	118	178	285	1.49E-06	49.3	CP1A1_MOUSE	reviewed	Cytochrome P450 1A1 (EC 1.14.14.1) (CYPIA1) (Cytochrome P450-P1)	Cyp1a1 Cyp1a-1	Mus musculus (Mouse)	524	9-cis-retinoic acid biosynthetic process [GO:0042904]; aging [GO:0007568]; amine metabolic process [GO:0009308]; camera-type eye development [GO:0043010]; cell proliferation [GO:0008283]; cellular response to organic cyclic compound [GO:0071407]; coumarin metabolic process [GO:0009804]; digestive tract development [GO:0048565]; drug metabolic process [GO:0017144]; embryo development ending in birth or egg hatching [GO:0009792]; flavonoid metabolic process [GO:0009812]; hepatocyte differentiation [GO:0070365]; heterocycle metabolic process [GO:0046483]; hydrogen peroxide biosynthetic process [GO:0050665]; insecticide metabolic process [GO:0017143]; maternal process involved in parturition [GO:0060137]; oxidation-reduction process [GO:0055114]; porphyrin-containing compound metabolic process [GO:0006778]; positive regulation of G1/S transition of mitotic cell cycle [GO:1900087]; response to antibiotic [GO:0046677]; response to arsenic-containing substance [GO:0046685]; response to drug [GO:0042493]; response to food [GO:0032094]; response to herbicide [GO:0009635]; response to hyperoxia [GO:0055093]; response to hypoxia [GO:0001666]; response to immobilization stress [GO:0035902]; response to iron(III) ion [GO:0010041]; response to lipopolysaccharide [GO:0032496]; response to nematode [GO:0009624]; response to toxic substance [GO:0009636]; response to virus [GO:0009615]; response to vitamin A [GO:0033189]; response to wounding [GO:0009611]; toxin metabolic process [GO:0009404]	GO:0001666; GO:0004497; GO:0005506; GO:0005739; GO:0005789; GO:0006778; GO:0007568; GO:0008283; GO:0008395; GO:0009308; GO:0009404; GO:0009611; GO:0009615; GO:0009624; GO:0009635; GO:0009636; GO:0009792; GO:0009804; GO:0009812; GO:0010041; GO:0016491; GO:0016679; GO:0016711; GO:0016712; GO:0017143; GO:0017144; GO:0020037; GO:0031090; GO:0032094; GO:0032451; GO:0032496; GO:0033189; GO:0035902; GO:0042493; GO:0042904; GO:0043010; GO:0043231; GO:0046483; GO:0046677; GO:0046685; GO:0048565; GO:0050665; GO:0055093; GO:0055114; GO:0060137; GO:0070330; GO:0070365; GO:0070576; GO:0071407; GO:1900087	0	0	0	PF00067;	3191	m.34263	186407	54401	1397167	260581.6667	22764.5	44155.5	298899.5	131393	65384.5	302437	0.438380378
CHOYP_LOC100371845.2.3	P70549	m.30117	sp	NAC3_RAT	37.667	900	446	20	3	806	47	927	3.41E-179	541	NAC3_RAT	reviewed	Sodium/calcium exchanger 3 (Na(+)/Ca(2+)-exchange protein 3) (Solute carrier family 8 member 3)	Slc8a3 Ncx3	Rattus norvegicus (Rat)	927	calcium ion export from cell [GO:1990034]; calcium ion import into cell [GO:1990035]; calcium ion transport into cytosol [GO:0060402]; cell communication [GO:0007154]; cellular response to cAMP [GO:0071320]; cellular response to hypoxia [GO:0071456]; hematopoietic progenitor cell differentiation [GO:0002244]; learning [GO:0007612]; long-term synaptic potentiation [GO:0060291]; memory [GO:0007613]; mitochondrial calcium ion homeostasis [GO:0051560]; mitochondrial calcium ion transport [GO:0006851]; myelination [GO:0042552]; oligodendrocyte differentiation [GO:0048709]; regulation of skeletal muscle contraction [GO:0014819]; sodium ion transport [GO:0006814]; telencephalon development [GO:0021537]	GO:0002244; GO:0005432; GO:0005739; GO:0005741; GO:0005789; GO:0005874; GO:0005886; GO:0005887; GO:0006814; GO:0006851; GO:0007154; GO:0007612; GO:0007613; GO:0014819; GO:0016528; GO:0021537; GO:0030054; GO:0031594; GO:0042383; GO:0042552; GO:0042995; GO:0043025; GO:0043197; GO:0043204; GO:0046872; GO:0048471; GO:0048709; GO:0051560; GO:0060291; GO:0060402; GO:0071320; GO:0071456; GO:1990034; GO:1990035	0	0	0	PF03160;PF01699;PF16494;	3231	m.30117	146922	103382	237907	NA	792229.5	203138.5	569801	569759	813290	1669854.5	2.390329266
CHOYP_LOC100373888.9.9	P29590	m.66033	sp	PML_HUMAN	25.51	392	233	15	54	420	31	388	6.95E-18	92	PML_HUMAN	reviewed	Protein PML (Promyelocytic leukemia protein) (RING finger protein 71) (Tripartite motif-containing protein 19)	PML MYL PP8675 RNF71 TRIM19	Homo sapiens (Human)	882	"activation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0006919]; apoptotic process [GO:0006915]; branching involved in mammary gland duct morphogenesis [GO:0060444]; cell cycle arrest [GO:0007050]; cell fate commitment [GO:0045165]; cellular response to interleukin-4 [GO:0071353]; cellular senescence [GO:0090398]; circadian regulation of gene expression [GO:0032922]; common-partner SMAD protein phosphorylation [GO:0007182]; defense response to virus [GO:0051607]; DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest [GO:0006977]; endoplasmic reticulum calcium ion homeostasis [GO:0032469]; entrainment of circadian clock by photoperiod [GO:0043153]; extrinsic apoptotic signaling pathway [GO:0097191]; fibroblast migration [GO:0010761]; innate immune response [GO:0045087]; interferon-gamma-mediated signaling pathway [GO:0060333]; intrinsic apoptotic signaling pathway in response to DNA damage [GO:0008630]; intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator [GO:0042771]; intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress [GO:0070059]; intrinsic apoptotic signaling pathway in response to oxidative stress [GO:0008631]; maintenance of protein location in nucleus [GO:0051457]; myeloid cell differentiation [GO:0030099]; negative regulation of angiogenesis [GO:0016525]; negative regulation of cell growth [GO:0030308]; negative regulation of cell proliferation [GO:0008285]; negative regulation of interleukin-1 beta secretion [GO:0050713]; negative regulation of mitotic cell cycle [GO:0045930]; negative regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process [GO:2000059]; negative regulation of telomerase activity [GO:0051974]; negative regulation of telomere maintenance via telomerase [GO:0032211]; negative regulation of transcription, DNA-templated [GO:0045892]; negative regulation of translation in response to oxidative stress [GO:0032938]; negative regulation of viral release from host cell [GO:1902187]; PML body organization [GO:0030578]; positive regulation of apoptotic process involved in mammary gland involution [GO:0060058]; positive regulation of defense response to virus by host [GO:0002230]; positive regulation of extrinsic apoptotic signaling pathway [GO:2001238]; positive regulation of fibroblast proliferation [GO:0048146]; positive regulation of histone deacetylation [GO:0031065]; positive regulation of protein localization to chromosome, telomeric region [GO:1904816]; positive regulation of telomere maintenance [GO:0032206]; proteasome-mediated ubiquitin-dependent protein catabolic process [GO:0043161]; protein complex assembly [GO:0006461]; protein stabilization [GO:0050821]; protein sumoylation [GO:0016925]; protein targeting [GO:0006605]; regulation of calcium ion transport into cytosol [GO:0010522]; regulation of cell adhesion [GO:0030155]; regulation of circadian rhythm [GO:0042752]; regulation of double-strand break repair [GO:2000779]; regulation of MHC class I biosynthetic process [GO:0045343]; regulation of protein phosphorylation [GO:0001932]; regulation of signal transduction by p53 class mediator [GO:1901796]; regulation of transcription, DNA-templated [GO:0006355]; response to cytokine [GO:0034097]; response to gamma radiation [GO:0010332]; response to hypoxia [GO:0001666]; response to UV [GO:0009411]; retinoic acid receptor signaling pathway [GO:0048384]; SMAD protein import into nucleus [GO:0007184]; transcription, DNA-templated [GO:0006351]; transforming growth factor beta receptor signaling pathway [GO:0007179]"	GO:0000784; GO:0001666; GO:0001932; GO:0002230; GO:0003677; GO:0003713; GO:0005634; GO:0005654; GO:0005730; GO:0005737; GO:0005829; GO:0006351; GO:0006355; GO:0006461; GO:0006605; GO:0006915; GO:0006919; GO:0006977; GO:0007050; GO:0007179; GO:0007182; GO:0007184; GO:0008270; GO:0008285; GO:0008630; GO:0008631; GO:0009411; GO:0010332; GO:0010522; GO:0010761; GO:0016363; GO:0016525; GO:0016605; GO:0016925; GO:0030099; GO:0030155; GO:0030308; GO:0030578; GO:0031065; GO:0031625; GO:0031901; GO:0031965; GO:0032183; GO:0032206; GO:0032211; GO:0032469; GO:0032922; GO:0032938; GO:0034097; GO:0042406; GO:0042752; GO:0042771; GO:0042803; GO:0043153; GO:0043161; GO:0045087; GO:0045165; GO:0045343; GO:0045892; GO:0045930; GO:0046982; GO:0048146; GO:0048384; GO:0050713; GO:0050821; GO:0050897; GO:0051457; GO:0051607; GO:0051974; GO:0060058; GO:0060333; GO:0060444; GO:0070059; GO:0071353; GO:0090398; GO:0097191; GO:1901796; GO:1902187; GO:1904816; GO:2000059; GO:2000779; GO:2001238	0	0	0	PF12126;PF00643;	3376	m.66033	40813	36983	755180	29621	29284	39954	35112	38534	3508465	20899	4.084585275
CHOYP_LOC100647889.1.1	O43915	m.21149	sp	VEGFD_HUMAN	26.131	199	125	6	19	204	46	235	1.43E-07	55.8	VEGFD_HUMAN	reviewed	Vascular endothelial growth factor D (VEGF-D) (c-Fos-induced growth factor) (FIGF)	FIGF VEGFD	Homo sapiens (Human)	354	angiogenesis [GO:0001525]; cell proliferation [GO:0008283]; dopaminergic neuron differentiation [GO:0071542]; induction of positive chemotaxis [GO:0050930]; platelet degranulation [GO:0002576]; positive regulation of cell division [GO:0051781]; positive regulation of cell proliferation [GO:0008284]; positive regulation of interleukin-6 production [GO:0032755]; positive regulation of mast cell chemotaxis [GO:0060754]; regulation of vascular endothelial growth factor receptor signaling pathway [GO:0030947]; response to hypoxia [GO:0001666]; response to interleukin-1 [GO:0070555]; vascular endothelial growth factor receptor signaling pathway [GO:0048010]	GO:0001525; GO:0001666; GO:0002576; GO:0005161; GO:0005172; GO:0005576; GO:0005615; GO:0008283; GO:0008284; GO:0016020; GO:0030947; GO:0031093; GO:0032755; GO:0042056; GO:0048010; GO:0050930; GO:0051781; GO:0060754; GO:0070555; GO:0071542	0	0	0	PF00341;	3875	m.21149	22996.5	74360	64070	45418	28159	71791	46044	27615	49122	198592.5	1.673015508
CHOYP_LOC100647889.1.1	O43915	m.21149	sp	VEGFD_HUMAN	26.131	199	125	6	19	204	46	235	1.43E-07	55.8	VEGFD_HUMAN	reviewed	Vascular endothelial growth factor D (VEGF-D) (c-Fos-induced growth factor) (FIGF)	FIGF VEGFD	Homo sapiens (Human)	354	angiogenesis [GO:0001525]; cell proliferation [GO:0008283]; dopaminergic neuron differentiation [GO:0071542]; induction of positive chemotaxis [GO:0050930]; platelet degranulation [GO:0002576]; positive regulation of cell division [GO:0051781]; positive regulation of cell proliferation [GO:0008284]; positive regulation of interleukin-6 production [GO:0032755]; positive regulation of mast cell chemotaxis [GO:0060754]; regulation of vascular endothelial growth factor receptor signaling pathway [GO:0030947]; response to hypoxia [GO:0001666]; response to interleukin-1 [GO:0070555]; vascular endothelial growth factor receptor signaling pathway [GO:0048010]	GO:0001525; GO:0001666; GO:0002576; GO:0005161; GO:0005172; GO:0005576; GO:0005615; GO:0008283; GO:0008284; GO:0016020; GO:0030947; GO:0031093; GO:0032755; GO:0042056; GO:0048010; GO:0050930; GO:0051781; GO:0060754; GO:0070555; GO:0071542	0	0	0	PF00341;	3876	m.21150	24994956.75	13043192	75779.5	9700721	14315483.8	27694397	8337151.5	16444749	85551074.33	63441511.25	3.242691963
CHOYP_LOC100698842.1.1	Q08420	m.40947	sp	SODE_RAT	29.054	148	96	7	25	171	48	187	2.92E-09	57.8	SODE_RAT	reviewed	Extracellular superoxide dismutase [Cu-Zn] (EC-SOD) (EC 1.15.1.1) (Superoxide dismutase B)	Sod3 Sod-3	Rattus norvegicus (Rat)	244	response to copper ion [GO:0046688]; response to hypoxia [GO:0001666]; response to oxidative stress [GO:0006979]; response to superoxide [GO:0000303]	GO:0000303; GO:0001666; GO:0004784; GO:0005507; GO:0005615; GO:0005634; GO:0005737; GO:0005802; GO:0006979; GO:0008270; GO:0031012; GO:0046688; GO:0070062	0	0	cd00305;	PF00080;	3928	m.40947	186559	208482	1126469.5	365970	206897.75	35060	79125	547840.3333	44132	51690	0.361848359
CHOYP_LOC100705966.1.1	P02504	m.45957	sp	CRYAA_CHICK	34.94	83	53	1	54	135	69	151	3.90E-07	52	CRYAA_CHICK	reviewed	Alpha-crystallin A chain	CRYAA	Gallus gallus (Chicken)	173	actin filament organization [GO:0007015]; apoptotic process involved in morphogenesis [GO:0060561]; embryonic camera-type eye morphogenesis [GO:0048596]; lens fiber cell morphogenesis [GO:0070309]; microtubule-based process [GO:0007017]; mitochondrion organization [GO:0007005]; negative regulation of apoptotic process [GO:0043066]; negative regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043154]; negative regulation of gene expression [GO:0010629]; negative regulation of intracellular transport [GO:0032387]; positive regulation of cell growth [GO:0030307]; positive regulation of protein phosphorylation [GO:0001934]; protein homooligomerization [GO:0051260]; response to hydrogen peroxide [GO:0042542]; response to hypoxia [GO:0001666]; response to UV-A [GO:0070141]; tubulin complex assembly [GO:0007021]; visual perception [GO:0007601]	GO:0001666; GO:0001934; GO:0005212; GO:0005634; GO:0005737; GO:0007005; GO:0007015; GO:0007017; GO:0007021; GO:0007601; GO:0010629; GO:0030307; GO:0032387; GO:0042542; GO:0042802; GO:0043066; GO:0043154; GO:0046872; GO:0048596; GO:0051082; GO:0051260; GO:0060561; GO:0070062; GO:0070141; GO:0070309	0	0	0	PF00525;PF00011;	3947	m.45957	139058	252776.7143	753610.2857	163145	181214.5	436373.6	134394.8333	233121	292497.25	483273.3	1.060313607
CHOYP_LOC100706287.1.1	P10758	m.44791	sp	LITH_RAT	36.429	140	81	5	223	357	26	162	8.69E-21	91.3	LITH_RAT	reviewed	Lithostathine (Islet cells regeneration factor) (ICRF) (Islet of Langerhans regenerating protein) (REG) (Pancreatic stone protein) (PSP) (Pancreatic thread protein) (PTP)	Reg1 Reg	Rattus norvegicus (Rat)	165	calcium ion homeostasis [GO:0055074]; cellular response to chemokine [GO:1990869]; cellular response to gastrin [GO:1990878]; liver regeneration [GO:0097421]; midgut development [GO:0007494]; negative regulation of cell proliferation [GO:0008285]; pancreas regeneration [GO:1990798]; positive regulation of acinar cell proliferation [GO:1904699]; positive regulation of dendrite extension [GO:1903861]; positive regulation of gene expression [GO:0010628]; positive regulation of type B pancreatic cell proliferation [GO:1904692]; protein homooligomerization [GO:0051260]; protein homotetramerization [GO:0051289]; response to acetylsalicylate [GO:1903492]; response to gastrin [GO:1990867]; response to growth hormone-releasing hormone [GO:1990864]; response to hypoxia [GO:0001666]; response to nutrient levels [GO:0031667]; response to organic cyclic compound [GO:0014070]; response to water-immersion restraint stress [GO:1990785]; wound healing [GO:0042060]	GO:0001666; GO:0005102; GO:0005615; GO:0005829; GO:0007494; GO:0008083; GO:0008285; GO:0010628; GO:0014070; GO:0019902; GO:0019903; GO:0030246; GO:0030426; GO:0031667; GO:0032590; GO:0032809; GO:0042060; GO:0042588; GO:0042802; GO:0042803; GO:0043234; GO:0045178; GO:0048471; GO:0051260; GO:0051289; GO:0055074; GO:0097421; GO:1903492; GO:1903861; GO:1904692; GO:1904699; GO:1990785; GO:1990798; GO:1990864; GO:1990867; GO:1990869; GO:1990878	0	0	0	PF00059;	3949	m.44791	157243	29805	74519.5	457445	715383	17757.5	167426.6667	18565	1047033.333	1095611.75	1.635807035
CHOYP_LOC100744089.1.1	Q7ZVK3	m.58530	sp	SIR2_DANRE	53.134	367	145	8	10	368	20	367	1.88E-124	366	SIR2_DANRE	reviewed	NAD-dependent protein deacetylase sirtuin-2 (EC 3.5.1.-) (Regulatory protein SIR2 homolog 2) (SIR2-like protein 2)	sirt2 zgc:77003	Danio rerio (Zebrafish) (Brachydanio rerio)	379	cellular response to caloric restriction [GO:0061433]; cellular response to hypoxia [GO:0071456]; cellular response to oxidative stress [GO:0034599]; cilium morphogenesis [GO:0060271]; histone H4 deacetylation [GO:0070933]; negative regulation of autophagy [GO:0010507]; negative regulation of cell proliferation [GO:0008285]; negative regulation of oligodendrocyte progenitor proliferation [GO:0070446]; negative regulation of protein catabolic process [GO:0042177]; negative regulation of reactive oxygen species metabolic process [GO:2000378]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; negative regulation of transcription from RNA polymerase II promoter in response to hypoxia [GO:0061428]; positive regulation of DNA binding [GO:0043388]; positive regulation of execution phase of apoptosis [GO:1900119]; positive regulation of proteasomal ubiquitin-dependent protein catabolic process [GO:0032436]; positive regulation of proteasomal ubiquitin-dependent protein catabolic process involved in cellular response to hypoxia [GO:2000777]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; protein deacetylation [GO:0006476]; regulation of cell cycle [GO:0051726]; tubulin deacetylation [GO:0090042]	GO:0000122; GO:0004407; GO:0005634; GO:0005694; GO:0005720; GO:0005737; GO:0005813; GO:0005814; GO:0005819; GO:0005829; GO:0006476; GO:0008270; GO:0008285; GO:0010507; GO:0030496; GO:0032436; GO:0033010; GO:0033270; GO:0034599; GO:0034979; GO:0042177; GO:0042903; GO:0043204; GO:0043209; GO:0043220; GO:0043388; GO:0044224; GO:0045944; GO:0046970; GO:0048471; GO:0051726; GO:0060271; GO:0061428; GO:0061433; GO:0070403; GO:0070446; GO:0070933; GO:0071456; GO:0072686; GO:0072687; GO:0090042; GO:0097386; GO:1900119; GO:2000378; GO:2000777	0	0	0	PF02146;	4005	m.58530	326315	40446	97110	197819.5	50139	341792	61122	169866	1138766.5	213182.6667	2.703918799
CHOYP_LOC100863386.1.1	P98156	m.37224	sp	VLDLR_MOUSE	41.638	879	448	24	26	888	25	854	0	645	VLDLR_MOUSE	reviewed	Very low-density lipoprotein receptor (VLDL receptor) (VLDL-R)	Vldlr	Mus musculus (Mouse)	873	cellular response to glucose starvation [GO:0042149]; cellular response to hypoxia [GO:0071456]; cellular response to insulin stimulus [GO:0032869]; cellular response to interleukin-1 [GO:0071347]; cellular response to lipopolysaccharide [GO:0071222]; cerebral cortex development [GO:0021987]; cholesterol metabolic process [GO:0008203]; dendrite morphogenesis [GO:0048813]; glycoprotein transport [GO:0034436]; heart development [GO:0007507]; lipid transport [GO:0006869]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; positive regulation of dendrite development [GO:1900006]; positive regulation of protein kinase activity [GO:0045860]; receptor-mediated endocytosis [GO:0006898]; reelin-mediated signaling pathway [GO:0038026]; response to drug [GO:0042493]; response to nutrient [GO:0007584]; ventral spinal cord development [GO:0021517]; very-low-density lipoprotein particle clearance [GO:0034447]	GO:0000122; GO:0001948; GO:0005509; GO:0005615; GO:0005634; GO:0005905; GO:0006869; GO:0006898; GO:0007507; GO:0007584; GO:0008203; GO:0009986; GO:0016020; GO:0016021; GO:0021517; GO:0021987; GO:0030229; GO:0032869; GO:0034185; GO:0034189; GO:0034361; GO:0034436; GO:0034437; GO:0034447; GO:0038025; GO:0038026; GO:0042149; GO:0042493; GO:0043235; GO:0045177; GO:0045860; GO:0048306; GO:0048471; GO:0048813; GO:0071222; GO:0071347; GO:0071456; GO:1900006	0	0	0	PF07645;PF00057;PF00058;	4040	m.37225	3594719.75	136020.3846	3237020.143	1057946.05	187084.25	880004.8667	2813725.286	5475459.308	3534083.882	155017.8462	1.565642161
CHOYP_LOC100880948.1.1	P52632	m.25232	sp	STA5B_RAT	43.182	792	403	19	141	917	1	760	0	592	STA5B_RAT	reviewed	Signal transducer and activator of transcription 5B	Stat5b	Rattus norvegicus (Rat)	786	"acute-phase response [GO:0006953]; cellular response to epidermal growth factor stimulus [GO:0071364]; cellular response to growth factor stimulus [GO:0071363]; JAK-STAT cascade [GO:0007259]; liver development [GO:0001889]; luteinization [GO:0001553]; positive regulation of cellular component movement [GO:0051272]; positive regulation of erythrocyte differentiation [GO:0045648]; positive regulation of smooth muscle cell proliferation [GO:0048661]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; prolactin signaling pathway [GO:0038161]; regulation of transcription, DNA-templated [GO:0006355]; response to ethanol [GO:0045471]; response to hypoxia [GO:0001666]; response to lipopolysaccharide [GO:0032496]; response to peptide hormone [GO:0043434]; transcription from RNA polymerase II promoter [GO:0006366]"	GO:0001553; GO:0001666; GO:0001889; GO:0003677; GO:0003682; GO:0003690; GO:0003700; GO:0004871; GO:0005634; GO:0005737; GO:0005829; GO:0006355; GO:0006366; GO:0006953; GO:0007259; GO:0032496; GO:0038161; GO:0043434; GO:0043565; GO:0045471; GO:0045648; GO:0045944; GO:0046983; GO:0048661; GO:0051272; GO:0071363; GO:0071364	0	0	0	PF00017;PF01017;PF02864;PF02865;	4104	m.25232	295672.5	399251	3281130	755412	255457.75	53087	291918	40593	1876974.5	181851.6667	0.490166791
CHOYP_LOC100883864.1.1	Q9WUB3	m.41791	sp	PYGM_MOUSE	72.738	840	229	0	5	844	3	842	0	1299	PYGM_MOUSE	reviewed	"Glycogen phosphorylase, muscle form (EC 2.4.1.1) (Myophosphorylase)"	Pygm	Mus musculus (Mouse)	842	cellular calcium ion homeostasis [GO:0006874]; glycogen catabolic process [GO:0005980]; response to cAMP [GO:0051591]; response to hypoxia [GO:0001666]	GO:0001666; GO:0005737; GO:0005980; GO:0006874; GO:0008144; GO:0008184; GO:0016208; GO:0016529; GO:0030018; GO:0030170; GO:0030246; GO:0051591; GO:0070062	0	0	cd04300;	PF00343;	4117	m.41791	562955.05	528880.3571	1453844.429	513138.5294	491681.9375	1027300.12	758127.1875	483973.0588	5079834.875	411525.95	2.185821864
CHOYP_LOC101169658.1.3	Q08420	m.18820	sp	SODE_RAT	29.268	164	96	7	318	467	65	222	1.04E-08	59.3	SODE_RAT	reviewed	Extracellular superoxide dismutase [Cu-Zn] (EC-SOD) (EC 1.15.1.1) (Superoxide dismutase B)	Sod3 Sod-3	Rattus norvegicus (Rat)	244	response to copper ion [GO:0046688]; response to hypoxia [GO:0001666]; response to oxidative stress [GO:0006979]; response to superoxide [GO:0000303]	GO:0000303; GO:0001666; GO:0004784; GO:0005507; GO:0005615; GO:0005634; GO:0005737; GO:0005802; GO:0006979; GO:0008270; GO:0031012; GO:0046688; GO:0070062	0	0	cd00305;	PF00080;	4295	m.18820	3199548.667	31548	NA	34315	558122	644544.5	NA	219611	102210	345421	0.343082241
CHOYP_LOC101169658.2.3	Q08420	m.20752	sp	SODE_RAT	25.654	191	112	8	147	323	48	222	4.94E-09	59.3	SODE_RAT	reviewed	Extracellular superoxide dismutase [Cu-Zn] (EC-SOD) (EC 1.15.1.1) (Superoxide dismutase B)	Sod3 Sod-3	Rattus norvegicus (Rat)	244	response to copper ion [GO:0046688]; response to hypoxia [GO:0001666]; response to oxidative stress [GO:0006979]; response to superoxide [GO:0000303]	GO:0000303; GO:0001666; GO:0004784; GO:0005507; GO:0005615; GO:0005634; GO:0005737; GO:0005802; GO:0006979; GO:0008270; GO:0031012; GO:0046688; GO:0070062	0	0	cd00305;	PF00080;	4296	m.20752	149280	127898	715463.6	218126.3333	144283	501606.1429	376881.6667	846515.83	427851.1667	385176.1667	1.873015184
CHOYP_LOC586005.1.1	Q8WVM8	m.63556	sp	SCFD1_HUMAN	66.981	636	196	6	13	641	14	642	0	884	SCFD1_HUMAN	reviewed	Sec1 family domain-containing protein 1 (SLY1 homolog) (Sly1p) (Syntaxin-binding protein 1-like 2)	SCFD1 C14orf163 KIAA0917 STXBP1L2 FKSG23	Homo sapiens (Human)	642	"cell morphogenesis [GO:0000902]; COPII vesicle coating [GO:0048208]; negative regulation of autophagosome assembly [GO:1902902]; phagocytosis [GO:0006909]; post-Golgi vesicle-mediated transport [GO:0006892]; protein transport [GO:0015031]; regulation of ER to Golgi vesicle-mediated transport [GO:0060628]; regulation of protein transport [GO:0051223]; response to hypoxia [GO:0001666]; response to toxic substance [GO:0009636]; retrograde vesicle-mediated transport, Golgi to ER [GO:0006890]; toxin transport [GO:1901998]; vesicle docking involved in exocytosis [GO:0006904]"	GO:0000902; GO:0001666; GO:0005789; GO:0005798; GO:0005801; GO:0005829; GO:0005886; GO:0006890; GO:0006892; GO:0006904; GO:0006909; GO:0009636; GO:0015031; GO:0017119; GO:0019905; GO:0032580; GO:0048208; GO:0051223; GO:0060628; GO:1901998; GO:1902902	0	0	0	PF00995;	4503	m.63556	491936	4159614	43599.28571	318459	148023.6667	627927.75	146851.1667	146067.8	492789.5714	488943.9	0.368600513
CHOYP_LOC587972.1.2	P09848	m.3283	sp	LPH_HUMAN	47.445	959	470	10	22	962	898	1840	0	909	LPH_HUMAN	reviewed	Lactase-phlorizin hydrolase (Lactase-glycosylceramidase) [Includes: Lactase (EC 3.2.1.108); Phlorizin hydrolase (EC 3.2.1.62)]	LCT LPH	Homo sapiens (Human)	1927	carbohydrate metabolic process [GO:0005975]; glycosyl compound metabolic process [GO:1901657]; polysaccharide digestion [GO:0044245]; response to drug [GO:0042493]; response to estrogen [GO:0043627]; response to ethanol [GO:0045471]; response to hormone [GO:0009725]; response to hypoxia [GO:0001666]; response to iron(II) ion [GO:0010040]; response to lead ion [GO:0010288]; response to nickel cation [GO:0010045]; response to nutrient [GO:0007584]; response to starvation [GO:0042594]; response to sucrose [GO:0009744]	GO:0000016; GO:0001666; GO:0005886; GO:0005887; GO:0005903; GO:0005975; GO:0007584; GO:0008422; GO:0009725; GO:0009744; GO:0010040; GO:0010045; GO:0010288; GO:0016020; GO:0016324; GO:0016740; GO:0017042; GO:0042493; GO:0042594; GO:0043627; GO:0044245; GO:0045471; GO:1901657	0	0	0	PF00232;	4526	m.3283	230455	25698	114081	614894.3333	701075.5	123326	98120	96491	104802.5	296171	0.426348515
CHOYP_LONM.1.1	Q8CGK3	m.7031	sp	LONM_MOUSE	56.443	939	362	11	80	1010	41	940	0	1064	LONM_MOUSE	reviewed	"Lon protease homolog, mitochondrial (EC 3.4.21.-) (Lon protease-like protein) (LONP) (Mitochondrial ATP-dependent protease Lon) (Serine protease 15)"	Lonp1 Prss15	Mus musculus (Mouse)	949	aging [GO:0007568]; cellular response to oxidative stress [GO:0034599]; chaperone-mediated protein complex assembly [GO:0051131]; misfolded or incompletely synthesized protein catabolic process [GO:0006515]; mitochondrion organization [GO:0007005]; oxidation-dependent protein catabolic process [GO:0070407]; protein homooligomerization [GO:0051260]; proteolysis [GO:0006508]; proteolysis involved in cellular protein catabolic process [GO:0051603]; regulation of mitochondrial DNA replication [GO:0090296]; response to aluminum ion [GO:0010044]; response to hormone [GO:0009725]; response to hypoxia [GO:0001666]	GO:0001666; GO:0003697; GO:0003727; GO:0004176; GO:0004252; GO:0005524; GO:0005634; GO:0005654; GO:0005737; GO:0005739; GO:0005759; GO:0006508; GO:0006515; GO:0007005; GO:0007568; GO:0009725; GO:0010044; GO:0016020; GO:0016887; GO:0034599; GO:0042645; GO:0043531; GO:0043565; GO:0051131; GO:0051260; GO:0051603; GO:0051880; GO:0070182; GO:0070361; GO:0070407; GO:0090296	0	0	0	PF00004;PF05362;PF02190;	4738	m.7031	341798.3636	228530.4545	1670853.929	462345.0769	8692922.643	279741.8333	6474960.125	382523.8182	175739.3529	332510.4737	0.670864637
CHOYP_MPI.1.1	O54698	m.35644	sp	S29A1_RAT	30.176	454	259	10	68	470	4	450	1.73E-54	192	S29A1_RAT	reviewed	"Equilibrative nucleoside transporter 1 (Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter) (Equilibrative NBMPR-sensitive nucleoside transporter) (Nucleoside transporter, es-type) (Solute carrier family 29 member 1)"	Slc29a1 Ent1	Rattus norvegicus (Rat)	457	cellular response to glucose stimulus [GO:0071333]; cellular response to hypoxia [GO:0071456]; excitatory postsynaptic potential [GO:0060079]; lactation [GO:0007595]; nucleoside transport [GO:0015858]; sleep [GO:0030431]; uridine transport [GO:0015862]	GO:0005337; GO:0005886; GO:0005887; GO:0007595; GO:0015858; GO:0015862; GO:0016323; GO:0016324; GO:0030431; GO:0060079; GO:0071333; GO:0071456; GO:0098794	0	0	0	PF01733;	4866	m.35645	167168	73713.5	155823	167448	314930	207562.3333	118404	564022.3333	179422	524575.4	1.81323831
CHOYP_MTOR.2.2	P42345	m.51573	sp	MTOR_HUMAN	64.88	2537	818	16	8	2479	21	2549	0	3351	MTOR_HUMAN	reviewed	Serine/threonine-protein kinase mTOR (EC 2.7.11.1) (FK506-binding protein 12-rapamycin complex-associated protein 1) (FKBP12-rapamycin complex-associated protein) (Mammalian target of rapamycin) (mTOR) (Mechanistic target of rapamycin) (Rapamycin and FKBP12 target 1) (Rapamycin target protein 1)	MTOR FRAP FRAP1 FRAP2 RAFT1 RAPT1	Homo sapiens (Human)	2549	'de novo' pyrimidine nucleobase biosynthetic process [GO:0006207]; brain development [GO:0007420]; cardiac muscle cell development [GO:0055013]; cardiac muscle contraction [GO:0060048]; cell aging [GO:0007569]; cell cycle arrest [GO:0007050]; cell growth [GO:0016049]; cellular response to hypoxia [GO:0071456]; cellular response to nutrient levels [GO:0031669]; DNA repair [GO:0006281]; energy reserve metabolic process [GO:0006112]; germ cell development [GO:0007281]; growth [GO:0040007]; heart morphogenesis [GO:0003007]; heart valve morphogenesis [GO:0003179]; long-term memory [GO:0007616]; macroautophagy [GO:0016236]; maternal process involved in female pregnancy [GO:0060135]; mRNA stabilization [GO:0048255]; multicellular organism growth [GO:0035264]; negative regulation of autophagy [GO:0010507]; negative regulation of cell size [GO:0045792]; negative regulation of cholangiocyte apoptotic process [GO:1904193]; negative regulation of iodide transmembrane transport [GO:1904213]; negative regulation of macroautophagy [GO:0016242]; negative regulation of muscle atrophy [GO:0014736]; negative regulation of NFAT protein import into nucleus [GO:0051534]; negative regulation of protein phosphorylation [GO:0001933]; negative regulation of protein ubiquitination [GO:0031397]; peptidyl-serine phosphorylation [GO:0018105]; peptidyl-threonine phosphorylation [GO:0018107]; phosphatidylinositol-mediated signaling [GO:0048015]; phosphorylation [GO:0016310]; positive regulation of actin filament polymerization [GO:0030838]; positive regulation of cell growth involved in cardiac muscle cell development [GO:0061051]; positive regulation of cholangiocyte proliferation [GO:1904056]; positive regulation of dendritic spine development [GO:0060999]; positive regulation of eating behavior [GO:1904000]; positive regulation of endothelial cell proliferation [GO:0001938]; positive regulation of gene expression [GO:0010628]; positive regulation of glial cell proliferation [GO:0060252]; positive regulation of granulosa cell proliferation [GO:1904197]; positive regulation of lamellipodium assembly [GO:0010592]; positive regulation of lipid biosynthetic process [GO:0046889]; positive regulation of myotube differentiation [GO:0010831]; positive regulation of neuron death [GO:1901216]; positive regulation of neuron maturation [GO:0014042]; positive regulation of nitric oxide biosynthetic process [GO:0045429]; positive regulation of oligodendrocyte differentiation [GO:0048714]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; positive regulation of protein kinase B signaling [GO:0051897]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of sensory perception of pain [GO:1904058]; positive regulation of skeletal muscle hypertrophy [GO:1904206]; positive regulation of smooth muscle cell proliferation [GO:0048661]; positive regulation of stress fiber assembly [GO:0051496]; positive regulation of transcription from RNA polymerase III promoter [GO:0045945]; positive regulation of transcription of nuclear large rRNA transcript from RNA polymerase I promoter [GO:1901838]; positive regulation of translation [GO:0045727]; post-embryonic development [GO:0009791]; protein autophosphorylation [GO:0046777]; protein catabolic process [GO:0030163]; protein phosphorylation [GO:0006468]; regulation of actin cytoskeleton organization [GO:0032956]; regulation of brown fat cell differentiation [GO:0090335]; regulation of carbohydrate utilization [GO:0043610]; regulation of cellular response to heat [GO:1900034]; regulation of fatty acid beta-oxidation [GO:0031998]; regulation of glycogen biosynthetic process [GO:0005979]; regulation of GTPase activity [GO:0043087]; regulation of membrane permeability [GO:0090559]; regulation of myelination [GO:0031641]; regulation of osteoclast differentiation [GO:0045670]; regulation of protein kinase activity [GO:0045859]; regulation of response to food [GO:0032095]; response to amino acid [GO:0043200]; response to cocaine [GO:0042220]; response to insulin [GO:0032868]; response to morphine [GO:0043278]; response to nutrient [GO:0007584]; response to stress [GO:0006950]; ruffle organization [GO:0031529]; signal transduction [GO:0007165]; social behavior [GO:0035176]; spinal cord development [GO:0021510]; T cell costimulation [GO:0031295]; TOR signaling [GO:0031929]; visual learning [GO:0008542]; voluntary musculoskeletal movement [GO:0050882]; wound healing [GO:0042060]	GO:0000139; GO:0001030; GO:0001031; GO:0001032; GO:0001156; GO:0001933; GO:0001934; GO:0001938; GO:0003007; GO:0003179; GO:0004672; GO:0004674; GO:0005524; GO:0005634; GO:0005654; GO:0005737; GO:0005741; GO:0005764; GO:0005765; GO:0005789; GO:0005829; GO:0005942; GO:0005979; GO:0006112; GO:0006207; GO:0006281; GO:0006468; GO:0006950; GO:0007050; GO:0007165; GO:0007281; GO:0007420; GO:0007569; GO:0007584; GO:0007616; GO:0008542; GO:0009791; GO:0010507; GO:0010592; GO:0010628; GO:0010831; GO:0012505; GO:0014042; GO:0014736; GO:0016020; GO:0016049; GO:0016236; GO:0016242; GO:0016301; GO:0016310; GO:0016605; GO:0018105; GO:0018107; GO:0021510; GO:0030163; GO:0030425; GO:0030838; GO:0031295; GO:0031397; GO:0031529; GO:0031641; GO:0031669; GO:0031929; GO:0031931; GO:0031932; GO:0031998; GO:0032095; GO:0032868; GO:0032956; GO:0035176; GO:0035264; GO:0040007; GO:0042060; GO:0042220; GO:0043022; GO:0043025; GO:0043087; GO:0043200; GO:0043278; GO:0043610; GO:0045429; GO:0045670; GO:0045727; GO:0045792; GO:0045859; GO:0045945; GO:0046777; GO:0046889; GO:0048015; GO:0048255; GO:0048661; GO:0048714; GO:0050731; GO:0050882; GO:0051219; GO:0051496; GO:0051534; GO:0051897; GO:0055013; GO:0060048; GO:0060135; GO:0060252; GO:0060999; GO:0061051; GO:0071456; GO:0090335; GO:0090559; GO:1900034; GO:1901216; GO:1901838; GO:1904000; GO:1904056; GO:1904058; GO:1904193; GO:1904197; GO:1904206; GO:1904213	0	0	0	PF11865;PF02259;PF02260;PF08771;PF00454;	4888	m.51573	134636.5	101621	83347	141601	109201	144805.5	56245	409431.5	1509876.333	22049	3.755930784
CHOYP_OGT1.3.3	P56558	m.54325	sp	OGT1_RAT	77.51	1036	212	6	3	1029	4	1027	0	1670	OGT1_RAT	reviewed	UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit (EC 2.4.1.255) (O-GlcNAc transferase subunit p110) (O-linked N-acetylglucosamine transferase 110 kDa subunit) (OGT)	Ogt	Rattus norvegicus (Rat)	1036	apoptotic process [GO:0006915]; cellular response to glucose stimulus [GO:0071333]; cellular response to insulin stimulus [GO:0032869]; cellular response to lipopolysaccharide [GO:0071222]; cellular response to toxic substance [GO:0097237]; circadian regulation of gene expression [GO:0032922]; forebrain development [GO:0030900]; glucosamine metabolic process [GO:0006041]; histone H3-K4 trimethylation [GO:0080182]; histone H4-K16 acetylation [GO:0043984]; histone H4-K5 acetylation [GO:0043981]; histone H4-K8 acetylation [GO:0043982]; intracellular distribution of mitochondria [GO:0048312]; negative regulation of cell death [GO:0060548]; negative regulation of cellular response to hypoxia [GO:1900038]; negative regulation of peptidyl-serine phosphorylation [GO:0033137]; negative regulation of peptidyl-threonine phosphorylation [GO:0010801]; negative regulation of protein phosphorylation [GO:0001933]; negative regulation of protein targeting to membrane [GO:0090315]; negative regulation of protein ubiquitination [GO:0031397]; phosphatidylinositol-mediated signaling [GO:0048015]; positive regulation of cell size [GO:0045793]; positive regulation of gene expression [GO:0010628]; positive regulation of histone H3-K27 methylation [GO:0061087]; positive regulation of protein localization to nucleus [GO:1900182]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of proteolysis [GO:0045862]; positive regulation of reactive oxygen species biosynthetic process [GO:1903428]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; protein heterotrimerization [GO:0070208]; protein homotrimerization [GO:0070207]; protein O-linked glycosylation [GO:0006493]; regulation of gluconeogenesis involved in cellular glucose homeostasis [GO:0090526]; regulation of glycolytic process [GO:0006110]	GO:0000123; GO:0000791; GO:0001933; GO:0001934; GO:0005547; GO:0005634; GO:0005737; GO:0005739; GO:0005829; GO:0005886; GO:0006041; GO:0006110; GO:0006493; GO:0006915; GO:0008134; GO:0010628; GO:0010801; GO:0016262; GO:0019904; GO:0030900; GO:0031397; GO:0032869; GO:0032922; GO:0033137; GO:0042277; GO:0042588; GO:0043005; GO:0043025; GO:0043981; GO:0043982; GO:0043984; GO:0045793; GO:0045862; GO:0045944; GO:0048015; GO:0048029; GO:0048312; GO:0060548; GO:0061087; GO:0070207; GO:0070208; GO:0071222; GO:0071333; GO:0080182; GO:0090315; GO:0090526; GO:0097237; GO:0097363; GO:1900038; GO:1900182; GO:1903428	PATHWAY: Protein modification; protein glycosylation.	0	0	PF13844;PF00515;PF13414;PF13181;	5166	m.54325	560498	419457	615317	302697	241984	55294	40288	156475	149364.5	256968.6667	0.307665714
CHOYP_PCKG.1.2	P05153	m.43784	sp	PCKGC_CHICK	65.422	616	210	3	127	742	10	622	0	873	PCKGC_CHICK	reviewed	"Phosphoenolpyruvate carboxykinase, cytosolic [GTP] (PEPCK-C) (EC 4.1.1.32)"	PCK1	Gallus gallus (Chicken)	622	adult feeding behavior [GO:0008343]; aging [GO:0007568]; alanine metabolic process [GO:0006522]; aspartate metabolic process [GO:0006531]; cellular response to cAMP [GO:0071320]; cellular response to dexamethasone stimulus [GO:0071549]; cellular response to ethanol [GO:0071361]; cellular response to fructose stimulus [GO:0071332]; cellular response to glucagon stimulus [GO:0071377]; cellular response to glucose starvation [GO:0042149]; cellular response to glucose stimulus [GO:0071333]; cellular response to hypoxia [GO:0071456]; cellular response to insulin stimulus [GO:0032869]; cellular response to interleukin-1 [GO:0071347]; cellular response to parathyroid hormone stimulus [GO:0071374]; cellular response to retinoic acid [GO:0071300]; cellular response to tumor necrosis factor [GO:0071356]; developmental growth [GO:0048589]; digestion [GO:0007586]; eggshell formation [GO:0030703]; embryo development ending in birth or egg hatching [GO:0009792]; embryonic organ morphogenesis [GO:0048562]; gluconeogenesis [GO:0006094]; glutamate metabolic process [GO:0006536]; glutamine metabolic process [GO:0006541]; glycerol catabolic process [GO:0019563]; glycine metabolic process [GO:0006544]; hepatocyte differentiation [GO:0070365]; intestinal absorption [GO:0050892]; kidney interstitial fibroblast differentiation [GO:0072071]; lactate metabolic process [GO:0006089]; lipid catabolic process [GO:0016042]; malate transport [GO:0015743]; NADH regeneration [GO:0006735]; negative regulation of carbohydrate metabolic process [GO:0045912]; oviposition [GO:0018991]; positive regulation of cAMP-mediated signaling [GO:0043950]; positive regulation of carbohydrate metabolic process [GO:0045913]; positive regulation of gluconeogenesis [GO:0045722]; proline metabolic process [GO:0006560]; propionate catabolic process [GO:0019543]; pyruvate metabolic process [GO:0006090]; regulation of feeding behavior [GO:0060259]; regulation of gluconeogenesis [GO:0006111]; regulation of transcription by glucose [GO:0046015]; response to cAMP [GO:0051591]; response to cycloheximide [GO:0046898]; response to glucocorticoid [GO:0051384]; response to interleukin-6 [GO:0070741]; response to lipid [GO:0033993]; response to lipopolysaccharide [GO:0032496]; response to methionine [GO:1904640]; response to starvation [GO:0042594]; serine family amino acid metabolic process [GO:0009069]; sexual reproduction [GO:0019953]; vitellogenesis [GO:0007296]	GO:0003729; GO:0004613; GO:0005525; GO:0005829; GO:0006089; GO:0006090; GO:0006094; GO:0006111; GO:0006522; GO:0006531; GO:0006536; GO:0006541; GO:0006544; GO:0006560; GO:0006735; GO:0007296; GO:0007568; GO:0007586; GO:0008343; GO:0008906; GO:0009069; GO:0009792; GO:0015743; GO:0016042; GO:0018991; GO:0019157; GO:0019543; GO:0019563; GO:0019953; GO:0030145; GO:0030703; GO:0032496; GO:0032869; GO:0033993; GO:0042149; GO:0042594; GO:0043565; GO:0043950; GO:0045722; GO:0045912; GO:0045913; GO:0046015; GO:0046898; GO:0047134; GO:0048562; GO:0048589; GO:0050692; GO:0050892; GO:0051379; GO:0051384; GO:0051591; GO:0060259; GO:0070365; GO:0070741; GO:0071300; GO:0071320; GO:0071332; GO:0071333; GO:0071347; GO:0071356; GO:0071361; GO:0071374; GO:0071377; GO:0071456; GO:0071549; GO:0072071; GO:1904640	PATHWAY: Carbohydrate biosynthesis; gluconeogenesis.	0	0	PF00821;	5222	m.43784	1674214.063	790275.3846	214843.8333	747486.2	2380641.857	707431.3125	3332535.158	971939.2381	1184684.579	2012093.765	1.41347201
CHOYP_PCKG.1.2	P05153	m.43784	sp	PCKGC_CHICK	65.422	616	210	3	127	742	10	622	0	873	PCKGC_CHICK	reviewed	"Phosphoenolpyruvate carboxykinase, cytosolic [GTP] (PEPCK-C) (EC 4.1.1.32)"	PCK1	Gallus gallus (Chicken)	622	adult feeding behavior [GO:0008343]; aging [GO:0007568]; alanine metabolic process [GO:0006522]; aspartate metabolic process [GO:0006531]; cellular response to cAMP [GO:0071320]; cellular response to dexamethasone stimulus [GO:0071549]; cellular response to ethanol [GO:0071361]; cellular response to fructose stimulus [GO:0071332]; cellular response to glucagon stimulus [GO:0071377]; cellular response to glucose starvation [GO:0042149]; cellular response to glucose stimulus [GO:0071333]; cellular response to hypoxia [GO:0071456]; cellular response to insulin stimulus [GO:0032869]; cellular response to interleukin-1 [GO:0071347]; cellular response to parathyroid hormone stimulus [GO:0071374]; cellular response to retinoic acid [GO:0071300]; cellular response to tumor necrosis factor [GO:0071356]; developmental growth [GO:0048589]; digestion [GO:0007586]; eggshell formation [GO:0030703]; embryo development ending in birth or egg hatching [GO:0009792]; embryonic organ morphogenesis [GO:0048562]; gluconeogenesis [GO:0006094]; glutamate metabolic process [GO:0006536]; glutamine metabolic process [GO:0006541]; glycerol catabolic process [GO:0019563]; glycine metabolic process [GO:0006544]; hepatocyte differentiation [GO:0070365]; intestinal absorption [GO:0050892]; kidney interstitial fibroblast differentiation [GO:0072071]; lactate metabolic process [GO:0006089]; lipid catabolic process [GO:0016042]; malate transport [GO:0015743]; NADH regeneration [GO:0006735]; negative regulation of carbohydrate metabolic process [GO:0045912]; oviposition [GO:0018991]; positive regulation of cAMP-mediated signaling [GO:0043950]; positive regulation of carbohydrate metabolic process [GO:0045913]; positive regulation of gluconeogenesis [GO:0045722]; proline metabolic process [GO:0006560]; propionate catabolic process [GO:0019543]; pyruvate metabolic process [GO:0006090]; regulation of feeding behavior [GO:0060259]; regulation of gluconeogenesis [GO:0006111]; regulation of transcription by glucose [GO:0046015]; response to cAMP [GO:0051591]; response to cycloheximide [GO:0046898]; response to glucocorticoid [GO:0051384]; response to interleukin-6 [GO:0070741]; response to lipid [GO:0033993]; response to lipopolysaccharide [GO:0032496]; response to methionine [GO:1904640]; response to starvation [GO:0042594]; serine family amino acid metabolic process [GO:0009069]; sexual reproduction [GO:0019953]; vitellogenesis [GO:0007296]	GO:0003729; GO:0004613; GO:0005525; GO:0005829; GO:0006089; GO:0006090; GO:0006094; GO:0006111; GO:0006522; GO:0006531; GO:0006536; GO:0006541; GO:0006544; GO:0006560; GO:0006735; GO:0007296; GO:0007568; GO:0007586; GO:0008343; GO:0008906; GO:0009069; GO:0009792; GO:0015743; GO:0016042; GO:0018991; GO:0019157; GO:0019543; GO:0019563; GO:0019953; GO:0030145; GO:0030703; GO:0032496; GO:0032869; GO:0033993; GO:0042149; GO:0042594; GO:0043565; GO:0043950; GO:0045722; GO:0045912; GO:0045913; GO:0046015; GO:0046898; GO:0047134; GO:0048562; GO:0048589; GO:0050692; GO:0050892; GO:0051379; GO:0051384; GO:0051591; GO:0060259; GO:0070365; GO:0070741; GO:0071300; GO:0071320; GO:0071332; GO:0071333; GO:0071347; GO:0071356; GO:0071361; GO:0071374; GO:0071377; GO:0071456; GO:0071549; GO:0072071; GO:1904640	PATHWAY: Carbohydrate biosynthesis; gluconeogenesis.	0	0	PF00821;	5223	m.43785	1341753.423	4351791.9	7164100.097	700227.1852	1642451.048	240488.8095	1599424.875	558461.619	50895915.29	662504.5217	3.549713568
CHOYP_PDIA1.1.1	P04785	m.5297	sp	PDIA1_RAT	61.475	488	178	3	18	495	22	509	0	617	PDIA1_RAT	reviewed	Protein disulfide-isomerase (PDI) (EC 5.3.4.1) (Cellular thyroid hormone-binding protein) (Prolyl 4-hydroxylase subunit beta)	P4hb Pdia1	Rattus norvegicus (Rat)	509	cell redox homeostasis [GO:0045454]; cellular response to hypoxia [GO:0071456]; peptidyl-proline hydroxylation to 4-hydroxy-L-proline [GO:0018401]; positive regulation of viral entry into host cell [GO:0046598]; protein folding [GO:0006457]; regulation of oxidative stress-induced intrinsic apoptotic signaling pathway [GO:1902175]; response to endoplasmic reticulum stress [GO:0034976]	GO:0003756; GO:0004656; GO:0005783; GO:0005788; GO:0005793; GO:0005925; GO:0006457; GO:0009897; GO:0016222; GO:0018401; GO:0019899; GO:0034663; GO:0034976; GO:0042470; GO:0044822; GO:0045454; GO:0046598; GO:0046982; GO:0070062; GO:0071456; GO:1902175	0	0	0	PF00085;	5236	m.5297	1418696.52	1427371.708	2906920.391	2269920.917	1160875	1183863.421	1490713.5	864647.2778	3997461.32	2991380.348	1.14637553
CHOYP_PSA.1.1	Q11011	m.27259	sp	PSA_MOUSE	62.946	869	318	3	59	925	44	910	0	1149	PSA_MOUSE	reviewed	Puromycin-sensitive aminopeptidase (PSA) (EC 3.4.11.14) (Cytosol alanyl aminopeptidase) (AAP-S)	Npepps Psa	Mus musculus (Mouse)	920	cellular response to hypoxia [GO:0071456]; peptide catabolic process [GO:0043171]; positive regulation of protein targeting to mitochondrion [GO:1903955]; proteolysis [GO:0006508]	GO:0004177; GO:0005634; GO:0005737; GO:0005829; GO:0005886; GO:0006508; GO:0008270; GO:0042277; GO:0043171; GO:0070006; GO:0070062; GO:0071456; GO:1903955	0	0	0	PF11838;PF01433;	5433	m.27259	630290.037	754576.3333	230574.9394	327062.0625	425302.6897	427042.3871	676494.2813	1253639.531	1455361.125	2761161.615	2.776282672
CHOYP_RL39.1.2	Q9D1L0	m.5372	sp	CHCH2_MOUSE	58.333	108	36	4	42	143	48	152	4.39E-33	117	CHCH2_MOUSE	reviewed	Coiled-coil-helix-coiled-coil-helix domain-containing protein 2	Chchd2	Mus musculus (Mouse)	153	"positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; regulation of cellular response to hypoxia [GO:1900037]; transcription, DNA-templated [GO:0006351]"	GO:0005634; GO:0005739; GO:0005758; GO:0006351; GO:0008134; GO:0043565; GO:0045944; GO:1900037	0	0	0	0	5648	m.5372	197323	787776	58945	351303.8	165321	110777.3333	58471	201661.5	64738.66667	648908	0.694930596
CHOYP_RS6.3.12	Q99MQ3	m.5754	sp	PINK1_MOUSE	35.749	414	221	8	117	521	128	505	3.53E-75	254	PINK1_MOUSE	reviewed	"Serine/threonine-protein kinase PINK1, mitochondrial (EC 2.7.11.1) (BRPK) (PTEN-induced putative kinase protein 1)"	Pink1	Mus musculus (Mouse)	580	"cellular response to hypoxia [GO:0071456]; cellular response to oxidative stress [GO:0034599]; cellular response to toxic substance [GO:0097237]; establishment of protein localization to mitochondrion [GO:0072655]; intracellular signal transduction [GO:0035556]; maintenance of protein location in mitochondrion [GO:0072656]; mitochondrion organization [GO:0007005]; mitophagy [GO:0000422]; mitophagy in response to mitochondrial depolarization [GO:0098779]; negative regulation of autophagosome assembly [GO:1902902]; negative regulation of gene expression [GO:0010629]; negative regulation of hydrogen peroxide-induced neuron intrinsic apoptotic signaling pathway [GO:1903384]; negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway [GO:1903298]; negative regulation of intrinsic apoptotic signaling pathway in response to hydrogen peroxide [GO:1903751]; negative regulation of macroautophagy [GO:0016242]; negative regulation of mitochondrial fission [GO:0090258]; negative regulation of mitophagy [GO:1903147]; negative regulation of neuron apoptotic process [GO:0043524]; negative regulation of oxidative stress-induced cell death [GO:1903202]; negative regulation of reactive oxygen species metabolic process [GO:2000378]; peptidyl-serine autophosphorylation [GO:0036289]; peptidyl-serine phosphorylation [GO:0018105]; positive regulation of catecholamine secretion [GO:0033605]; positive regulation of cristae formation [GO:1903852]; positive regulation of dopamine secretion [GO:0033603]; positive regulation of histone deacetylase activity [GO:1901727]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; positive regulation of macroautophagy [GO:0016239]; positive regulation of mitochondrial electron transport, NADH to ubiquinone [GO:1902958]; positive regulation of mitochondrial fission [GO:0090141]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; positive regulation of protein dephosphorylation [GO:0035307]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of protein targeting to mitochondrion [GO:1903955]; positive regulation of release of cytochrome c from mitochondria [GO:0090200]; positive regulation of sequence-specific DNA binding transcription factor activity [GO:0051091]; positive regulation of synaptic transmission, dopaminergic [GO:0032226]; positive regulation of translation [GO:0045727]; protein phosphorylation [GO:0006468]; protein stabilization [GO:0050821]; protein ubiquitination [GO:0016567]; regulation of hydrogen peroxide metabolic process [GO:0010310]; regulation of mitochondrial membrane potential [GO:0051881]; regulation of mitochondrion organization [GO:0010821]; regulation of neuron apoptotic process [GO:0043523]; regulation of oxidative phosphorylation [GO:0002082]; regulation of protein complex assembly [GO:0043254]; regulation of protein targeting to mitochondrion [GO:1903214]; regulation of protein ubiquitination [GO:0031396]; regulation of reactive oxygen species metabolic process [GO:2000377]; respiratory electron transport chain [GO:0022904]; response to oxidative stress [GO:0006979]; response to stress [GO:0006950]"	GO:0000287; GO:0000422; GO:0000785; GO:0001934; GO:0002020; GO:0002082; GO:0004672; GO:0004674; GO:0005524; GO:0005634; GO:0005737; GO:0005739; GO:0005741; GO:0005742; GO:0005743; GO:0005758; GO:0005829; GO:0005856; GO:0006468; GO:0006950; GO:0006979; GO:0007005; GO:0010310; GO:0010629; GO:0010821; GO:0010857; GO:0016020; GO:0016239; GO:0016242; GO:0016301; GO:0016567; GO:0018105; GO:0022904; GO:0030424; GO:0031307; GO:0031396; GO:0031625; GO:0031932; GO:0032226; GO:0033138; GO:0033603; GO:0033605; GO:0034599; GO:0035307; GO:0035556; GO:0036289; GO:0043123; GO:0043254; GO:0043422; GO:0043523; GO:0043524; GO:0044297; GO:0045727; GO:0048471; GO:0050821; GO:0051091; GO:0051881; GO:0055131; GO:0071456; GO:0072655; GO:0072656; GO:0090141; GO:0090200; GO:0090258; GO:0097237; GO:0097449; GO:0098779; GO:1901727; GO:1902902; GO:1902958; GO:1903147; GO:1903202; GO:1903214; GO:1903298; GO:1903384; GO:1903751; GO:1903852; GO:1903955; GO:2000377; GO:2000378	0	0	0	PF00069;	5899	m.5755	222333.6667	10068763.57	65457.95	106437.8571	18187961	7527201.75	516518.6	11119337.4	411293.75	56527.77381	0.685173668
CHOYP_SMAD3.1.1	P84025	m.51679	sp	SMAD3_RAT	76.941	425	87	3	1	414	1	425	0	674	SMAD3_RAT	reviewed	Mothers against decapentaplegic homolog 3 (MAD homolog 3) (Mad3) (Mothers against DPP homolog 3) (SMAD family member 3) (SMAD 3) (Smad3)	Smad3 Madh3	Rattus norvegicus (Rat)	425	"activation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0006919]; activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway [GO:0097296]; canonical Wnt signaling pathway [GO:0060070]; cell-cell junction organization [GO:0045216]; cell cycle arrest [GO:0007050]; developmental growth [GO:0048589]; embryonic cranial skeleton morphogenesis [GO:0048701]; embryonic foregut morphogenesis [GO:0048617]; embryonic pattern specification [GO:0009880]; endoderm development [GO:0007492]; evasion or tolerance of host defenses by virus [GO:0019049]; extrinsic apoptotic signaling pathway [GO:0097191]; heart looping [GO:0001947]; immune response [GO:0006955]; immune system development [GO:0002520]; intracellular signal transduction [GO:0035556]; in utero embryonic development [GO:0001701]; lens fiber cell differentiation [GO:0070306]; liver development [GO:0001889]; mesoderm formation [GO:0001707]; negative regulation of apoptotic process [GO:0043066]; negative regulation of cell growth [GO:0030308]; negative regulation of cell proliferation [GO:0008285]; negative regulation of fat cell differentiation [GO:0045599]; negative regulation of inflammatory response [GO:0050728]; negative regulation of mitotic cell cycle [GO:0045930]; negative regulation of osteoblast differentiation [GO:0045668]; negative regulation of osteoblast proliferation [GO:0033689]; negative regulation of protein catabolic process [GO:0042177]; negative regulation of protein phosphorylation [GO:0001933]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; negative regulation of wound healing [GO:0061045]; nodal signaling pathway [GO:0038092]; osteoblast development [GO:0002076]; paraxial mesoderm morphogenesis [GO:0048340]; pericardium development [GO:0060039]; positive regulation of alkaline phosphatase activity [GO:0010694]; positive regulation of bone mineralization [GO:0030501]; positive regulation of canonical Wnt signaling pathway [GO:0090263]; positive regulation of catenin import into nucleus [GO:0035413]; positive regulation of cell migration [GO:0030335]; positive regulation of chondrocyte differentiation [GO:0032332]; positive regulation of epithelial to mesenchymal transition [GO:0010718]; positive regulation of extracellular matrix assembly [GO:1901203]; positive regulation of focal adhesion assembly [GO:0051894]; positive regulation of interleukin-1 beta production [GO:0032731]; positive regulation of positive chemotaxis [GO:0050927]; positive regulation of stress fiber assembly [GO:0051496]; positive regulation of transcription factor import into nucleus [GO:0042993]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of transforming growth factor beta3 production [GO:0032916]; protein stabilization [GO:0050821]; regulation of binding [GO:0051098]; regulation of epithelial cell proliferation [GO:0050678]; regulation of immune response [GO:0050776]; regulation of striated muscle tissue development [GO:0016202]; regulation of transforming growth factor beta2 production [GO:0032909]; regulation of transforming growth factor beta receptor signaling pathway [GO:0017015]; response to hypoxia [GO:0001666]; signal transduction involved in regulation of gene expression [GO:0023019]; SMAD protein complex assembly [GO:0007183]; SMAD protein signal transduction [GO:0060395]; somitogenesis [GO:0001756]; T cell activation [GO:0042110]; thyroid gland development [GO:0030878]; transcription, DNA-templated [GO:0006351]; transdifferentiation [GO:0060290]; transforming growth factor beta receptor signaling pathway [GO:0007179]; transport [GO:0006810]; ureteric bud development [GO:0001657]"	GO:0000122; GO:0000790; GO:0000978; GO:0000983; GO:0000987; GO:0000988; GO:0001657; GO:0001666; GO:0001701; GO:0001707; GO:0001756; GO:0001889; GO:0001933; GO:0001947; GO:0002076; GO:0002520; GO:0003677; GO:0003700; GO:0005634; GO:0005637; GO:0005654; GO:0005667; GO:0005737; GO:0005886; GO:0006351; GO:0006810; GO:0006919; GO:0006955; GO:0007050; GO:0007179; GO:0007183; GO:0007492; GO:0008013; GO:0008134; GO:0008270; GO:0008285; GO:0009880; GO:0010694; GO:0010718; GO:0016202; GO:0017015; GO:0019049; GO:0019899; GO:0023019; GO:0030308; GO:0030335; GO:0030501; GO:0030618; GO:0030878; GO:0031490; GO:0032332; GO:0032731; GO:0032909; GO:0032916; GO:0033689; GO:0035413; GO:0035556; GO:0038092; GO:0042110; GO:0042177; GO:0042993; GO:0043066; GO:0043234; GO:0043235; GO:0043565; GO:0045216; GO:0045599; GO:0045668; GO:0045930; GO:0045944; GO:0046332; GO:0048340; GO:0048589; GO:0048617; GO:0048701; GO:0050678; GO:0050728; GO:0050776; GO:0050821; GO:0050927; GO:0051098; GO:0051496; GO:0051894; GO:0060039; GO:0060070; GO:0060290; GO:0060395; GO:0061045; GO:0070306; GO:0071141; GO:0071144; GO:0090263; GO:0097191; GO:0097296; GO:1901203	0	0	0	PF03165;PF03166;	6084	m.51679	197607	440337	30815	323514.25	443263	131741	72672	41552	1320392	89663.5	1.153590165
CHOYP_TBL2.1.1	Q9Y4P3	m.29917	sp	TBL2_HUMAN	52.32	388	178	2	60	444	59	442	5.38E-140	411	TBL2_HUMAN	reviewed	Transducin beta-like protein 2 (WS beta-transducin repeats protein) (WS-betaTRP) (Williams-Beuren syndrome chromosomal region 13 protein)	TBL2 WBSCR13 UNQ563/PRO1125	Homo sapiens (Human)	447	cellular response to glucose starvation [GO:0042149]; cellular response to hypoxia [GO:0071456]; endoplasmic reticulum unfolded protein response [GO:0030968]	GO:0005783; GO:0019901; GO:0030176; GO:0030968; GO:0031369; GO:0042149; GO:0044822; GO:0051219; GO:0071456	0	0	0	PF00400;	6325	m.29917	129679	15266	28434	49115	179557.5	70158.5	81512	32467	111747	49403	0.858814107
CHOYP_TRPC6.2.2	Q61143	m.56694	sp	TRPC6_MOUSE	37.349	913	488	16	6	882	56	920	0	597	TRPC6_MOUSE	reviewed	Short transient receptor potential channel 6 (TrpC6) (Calcium entry channel) (Transient receptor protein 6) (TRP-6)	Trpc6 Trp6 Trrp6	Mus musculus (Mouse)	930	aging [GO:0007568]; cellular response to hydrogen peroxide [GO:0070301]; cellular response to hypoxia [GO:0071456]; manganese ion transport [GO:0006828]; negative regulation of dendrite morphogenesis [GO:0050774]; neuron differentiation [GO:0030182]; positive regulation of calcium ion transport [GO:0051928]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of ion transmembrane transporter activity [GO:0032414]; positive regulation of neuron differentiation [GO:0045666]; positive regulation of peptidyl-threonine phosphorylation [GO:0010800]; single fertilization [GO:0007338]	GO:0005216; GO:0005737; GO:0005886; GO:0005887; GO:0006828; GO:0007204; GO:0007338; GO:0007568; GO:0010800; GO:0015279; GO:0016020; GO:0030182; GO:0032414; GO:0036057; GO:0045666; GO:0050774; GO:0051928; GO:0070301; GO:0070679; GO:0071456	0	0	0	PF12796;PF00520;PF08344;	6479	m.56694	511866	3165642	159221	12629796.33	3526284	6113079.5	83126.5	7643005	205573.5	731155	0.739062693
CHOYP_UBP37.1.1	Q08420	m.15559	sp	SODE_RAT	27.333	150	102	6	21	169	48	191	1.88E-10	61.6	SODE_RAT	reviewed	Extracellular superoxide dismutase [Cu-Zn] (EC-SOD) (EC 1.15.1.1) (Superoxide dismutase B)	Sod3 Sod-3	Rattus norvegicus (Rat)	244	response to copper ion [GO:0046688]; response to hypoxia [GO:0001666]; response to oxidative stress [GO:0006979]; response to superoxide [GO:0000303]	GO:0000303; GO:0001666; GO:0004784; GO:0005507; GO:0005615; GO:0005634; GO:0005737; GO:0005802; GO:0006979; GO:0008270; GO:0031012; GO:0046688; GO:0070062	0	0	cd00305;	PF00080;	6572	m.15559	149280	145904.5	715463.6	294631.5	178660.6667	579099.6667	494118	846515.83	402935	452613.6	1.870211463
CHOYP_UBQL4.1.1	Q8R317	m.37426	sp	UBQL1_MOUSE	51.171	598	216	12	7	573	25	577	0	527	UBQL1_MOUSE	reviewed	Ubiquilin-1 (Protein linking IAP with cytoskeleton 1) (PLIC-1)	Ubqln1 Plic1	Mus musculus (Mouse)	582	aggrephagy [GO:0035973]; autophagosome assembly [GO:0000045]; autophagosome maturation [GO:0097352]; cellular response to hypoxia [GO:0071456]; ER-associated ubiquitin-dependent protein catabolic process [GO:0030433]; macroautophagy [GO:0016236]; negative regulation of autophagosome maturation [GO:1901097]; negative regulation of store-operated calcium channel activity [GO:1901340]; negative regulation of toll-like receptor 3 signaling pathway [GO:0034140]; positive regulation of ER-associated ubiquitin-dependent protein catabolic process [GO:1903071]; positive regulation of protein ubiquitination [GO:0031398]; regulation of autophagosome assembly [GO:2000785]; regulation of oxidative stress-induced intrinsic apoptotic signaling pathway [GO:1902175]; regulation of protein ubiquitination [GO:0031396]; response to endoplasmic reticulum stress [GO:0034976]	GO:0000045; GO:0000502; GO:0005102; GO:0005654; GO:0005737; GO:0005776; GO:0005783; GO:0005886; GO:0016235; GO:0016236; GO:0019215; GO:0019900; GO:0030433; GO:0031396; GO:0031398; GO:0031410; GO:0031593; GO:0034140; GO:0034976; GO:0035973; GO:0042802; GO:0043234; GO:0048471; GO:0071456; GO:0097352; GO:1901097; GO:1901340; GO:1902175; GO:1903071; GO:2000785	0	0	0	PF00627;PF00240;	6575	m.37426	149614.875	613898.1429	1367740.857	689446.6667	1169927.333	1397881.714	272775.3333	5041098.571	350485.6667	77469.625	1.789119691
CHOYP_contig_050645	Q08420	m.60289	sp	SODE_RAT	26.667	150	103	6	31	179	48	191	1.87E-09	58.9	SODE_RAT	reviewed	Extracellular superoxide dismutase [Cu-Zn] (EC-SOD) (EC 1.15.1.1) (Superoxide dismutase B)	Sod3 Sod-3	Rattus norvegicus (Rat)	244	response to copper ion [GO:0046688]; response to hypoxia [GO:0001666]; response to oxidative stress [GO:0006979]; response to superoxide [GO:0000303]	GO:0000303; GO:0001666; GO:0004784; GO:0005507; GO:0005615; GO:0005634; GO:0005737; GO:0005802; GO:0006979; GO:0008270; GO:0031012; GO:0046688; GO:0070062	0	0	cd00305;	PF00080;	1664	m.60289	149280	145904.5	715463.6	294631.5	178660.6667	579099.6667	494118	846515.83	402935	452613.6	1.870211463